{"id":9814,"date":"2017-06-08T09:21:40","date_gmt":"2017-06-08T09:21:40","guid":{"rendered":"https:\/\/dejalex.com\/it\/industries\/pharmaceuticals-and-life-sciences\/"},"modified":"2026-11-09T22:07:34","modified_gmt":"2026-11-09T22:07:34","slug":"pharmaceuticals-and-life-sciences","status":"publish","type":"page","link":"https:\/\/www.dejalex.com\/it\/industries\/pharmaceuticals-and-life-sciences\/","title":{"rendered":"Farmaceutico e Life Sciences"},"content":{"rendered":"<div id=\"cs-content\" class=\"cs-content\"><div id=\"x-section-1\" class=\"x-section act_banner bg-image\" style=\"margin: 0px;padding: 45px 0px;margin: 0px;padding: 45px 0px; background-image: url(https:\/\/dejalex.com\/it\/wp-content\/uploads\/2018\/01\/pharma.jpg); background-color: transparent;\" data-x-element=\"section\" data-x-params=\"{&quot;type&quot;:&quot;image&quot;,&quot;parallax&quot;:false}\"><div id=\"\" class=\"x-container max width\" style=\"margin: 0px auto;padding: 0px;margin: 0px auto;padding: 0px;\" ><div  class=\"x-column x-sm x-1-1\" style=\"padding: 0px;padding: 0px;\" ><hr  class=\"x-gap\" style=\"margin: 320px 0 0 0;\"><\/div><\/div><\/div><div id=\"x-section-2\" class=\"x-section people-head-bg\" style=\"margin: 0px;padding: 45px 0px;margin: 0px;padding: 10px 0px 45px; background-color: transparent;\" ><div id=\"\" class=\"x-container max width\" style=\"margin: 0px auto;padding: 0px;margin: 0px auto;padding: 0px 30px;max-width:1000px;\" ><div  class=\"x-column x-sm x-1-1\" style=\"padding: 0px;padding: 0px 30px 40px; background-color:hsla(0, 0%, 100%, 0);\" ><div id=\"\" class=\"x-text cs-ta-right\" style=\"\" ><p> <a href=\"https:\/\/dejalex.com\/it\/industries\/?lang=it\"><i  class=\"x-icon x-icon-arrow-left\" data-x-icon-s=\"&#xf060;\" aria-hidden=\"true\"><\/i> industries<\/a><\/p>\n<\/div><h5  class=\"h-custom-headline h5\" ><span>Farmaceutico e Life Sciences<\/span><\/h5><div id=\"\" class=\"x-text\" style=\"\" ><p><span><\/p>\n<p>Il settore farmaceutico e delle life sciences \u00e8 tra i pi\u00f9 complessi e dinamici: \u00e8 caratterizzato da elevati standard regolatori, da un\u2019intensa attivit\u00e0 di ricerca e sviluppo e da una costante interazione con le Autorit\u00e0 sanitarie nazionali ed europee.<\/p>\n<p>In questo contesto, le imprese affrontano sfide articolate legate alla regolamentazione dei prodotti, all\u2019accesso al mercato e al rimborso, alla tutela dell\u2019innovazione, alla compliance dei modelli di business e alla sostenibilit\u00e0, in un mercato fortemente competitivo e in continua evoluzione.<\/p>\n<p><b><em>LA NOSTRA ESPERIENZA<\/em><\/b><\/p>\n<p>De Berti Jacchia vanta una <strong>storica e consolidata esperienza<\/strong> nell\u2019assistenza a <strong>case farmaceutiche<\/strong> e operatori del comparto life sciences, italiani e internazionali. Affianchiamo i clienti con un approccio multidisciplinare e pragmatico, integrando competenze regolatorie, societarie, contrattuali, contenziose e di tutela dell\u2019innovazione.<\/p>\n<p>Assistiamo i clienti lungo <strong>l\u2019intero ciclo di vita del prodotto<\/strong>, dalla ricerca e sviluppo e sperimentazione, alle autorizzazioni e al market access, fino alla commercializzazione, alla gestione dei rischi e al contenzioso, nonch\u00e9 nelle fasi di trasformazione strategica e <strong>operazioni straordinarie<\/strong>.<\/p>\n<p><b><em>I NOSTRI SERVIZI<\/em><\/b><\/p>\n<p>Assistiamo societ\u00e0 farmaceutiche, biotech, produttori di dispositivi medici e diagnostica, CRO, start-up innovative, investitori e operatori della filiera healthcare.<\/p>\n<p>In particolare, forniamo consulenza in relazione a:<\/p>\n<ul>\n<li><strong>Regolamentazione farmaceutica e dei dispositivi medici<\/strong> (nazionale ed europea), inclusi profili autorizzativi e requisiti di conformit\u00e0<\/li>\n<li><strong>Sperimentazioni cliniche<\/strong>, contrattualistica con centri sperimentali e CRO, e supporto alle funzioni interne coinvolte (medical, regulatory, quality)<\/li>\n<li><strong>Market access, pricing e rimborsabilit\u00e0<\/strong>, anche nei rapporti con Autorit\u00e0 competenti<\/li>\n<li><strong>Rapporti con AIFA, EMA e Autorit\u00e0 nazionali\/europee<\/strong>, nonch\u00e9 gestione di procedimenti e interlocuzioni istituzionali<\/li>\n<li><strong>Compliance, anticorruzione e modelli organizzativi ex D.Lgs. 231\/2001<\/strong>, inclusi programmi di controllo e formazione<\/li>\n<li><strong>Tutela dell\u2019innovazione e propriet\u00e0 intellettuale<\/strong>, strategie di protezione e valorizzazione, accordi di licenza e trasferimento tecnologico<\/li>\n<li><strong>Contrattualistica commerciale<\/strong> (supply, distribuzione, co-marketing\/co-promotion, servizi, qualit\u00e0) e <strong>accordi di collaborazione<\/strong> (R&amp;D, development, manufacturing)<\/li>\n<li><strong>Distribuzione e canali<\/strong> (farmacie, ospedali, grossisti, e-commerce e canali OTC, nei limiti applicabili), incluse politiche commerciali e compliance<\/li>\n<li><strong>Public procurement e gare<\/strong> nel settore sanitario, con assistenza in fase di partecipazione e nella gestione di controversie<\/li>\n<li><strong>Diritto della concorrenza<\/strong> e profili di compliance antitrust nel settore<\/li>\n<li><strong>Contenzioso regolatorio, civile e amministrativo<\/strong>, incluse misure cautelari e gestione del rischio<\/li>\n<li><strong>Product liability e product safety<\/strong>, inclusa gestione di richiami e azioni correttive, nonch\u00e9 supporto nella definizione di strategie difensive e coordinamento con consulenti tecnico-scientifici<\/li>\n<\/ul>\n<p><b><em>OPERAZIONI STRAORDINARIE NEL LIFE SCIENCES<\/em><\/b><\/p>\n<p>Assistiamo clienti e investitori in <strong>operazioni straordinarie<\/strong> nel settore life sciences, con focus su profili tipici del comparto (regolatorio, IP, supply chain, qualit\u00e0, farmacovigilanza\/tecnovigilanza, responsabilit\u00e0 da prodotto).<\/p>\n<p>Interveniamo, tra l\u2019altro, in:<\/p>\n<ul>\n<li><strong>M&amp;A e acquisizioni di asset\/prodotti\/portafogli<\/strong><\/li>\n<li><strong>Joint venture e partnership industriali<\/strong><\/li>\n<li><strong>Accordi di licensing e trasferimento tecnologico<\/strong><\/li>\n<li><strong>Accordi strategici<\/strong> (co-development, co-commercialization, co-promotion)<\/li>\n<li><strong>Riorganizzazioni societarie<\/strong> e carve-out, anche con supporto nella due diligence integrata e nella negoziazione della documentazione contrattuale<\/li>\n<\/ul>\n<\/div><ul  class=\"x-nav x-nav-tabs people-tab two-up top\"  data-x-element=\"tab_nav\" data-x-params=\"{&quot;orientation&quot;:&quot;horizontal&quot;}\" role=\"tablist\"><li  class=\"x-nav-tabs-item active\"  role=\"presentation\"><a id=\"x-legacy-tab-1\" aria-selected=\"true\" aria-controls=\"x-legacy-panel-1\" role=\"tab\" data-x-toggle=\"tab\" data-x-toggleable=\"x-legacy-tab-1\" data-x-toggle-group=\"6affd2667ce53\">Latest<\/a><\/li><li  class=\"x-nav-tabs-item hide\"  role=\"presentation\"><a id=\"x-legacy-tab-2\" aria-selected=\"false\" aria-controls=\"x-legacy-panel-2\" role=\"tab\" data-x-toggle=\"tab\" data-x-toggleable=\"x-legacy-tab-2\" data-x-toggle-group=\"6affd2667ce53\">Track record<\/a><\/li><\/ul><div  class=\"x-tab-content people-tab\" ><div id=\"x-legacy-panel-1\" class=\"x-tab-pane active\"  aria-hidden=\"false\" aria-labelledby=\"x-legacy-tab-1\" role=\"tabpanel\" data-x-toggleable=\"x-legacy-tab-1\"><style type=\"text\/css\">a.eg-henryharrison-element-1,a.eg-henryharrison-element-2{-webkit-transition:all .4s linear;   -moz-transition:all .4s linear;   -o-transition:all .4s linear;   -ms-transition:all .4s linear;   transition:all .4s linear}.eg-jimmy-carter-element-11 i:before{margin-left:0px; margin-right:0px}.eg-harding-element-17{letter-spacing:1px}.eg-harding-wrapper .esg-entry-media{overflow:hidden; box-sizing:border-box;   -webkit-box-sizing:border-box;   -moz-box-sizing:border-box;   padding:30px 30px 0px 30px}.eg-harding-wrapper .esg-media-poster{overflow:hidden; border-radius:50%;   -webkit-border-radius:50%;   -moz-border-radius:50%}.eg-ulysses-s-grant-wrapper .esg-entry-media{overflow:hidden; box-sizing:border-box;   -webkit-box-sizing:border-box;   -moz-box-sizing:border-box;   padding:30px 30px 0px 30px}.eg-ulysses-s-grant-wrapper .esg-media-poster{overflow:hidden; border-radius:50%;   -webkit-border-radius:50%;   -moz-border-radius:50%}.eg-richard-nixon-wrapper .esg-entry-media{overflow:hidden; box-sizing:border-box;   -webkit-box-sizing:border-box;   -moz-box-sizing:border-box;   padding:30px 30px 0px 30px}.eg-richard-nixon-wrapper .esg-media-poster{overflow:hidden; border-radius:50%;   -webkit-border-radius:50%;   -moz-border-radius:50%}.eg-herbert-hoover-wrapper .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");   filter:gray;   -webkit-filter:grayscale(100%)}.eg-herbert-hoover-wrapper:hover .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='1 0 0 0 0,0 1 0 0 0,0 0 1 0 0,0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");  -webkit-filter:grayscale(0%)}.eg-lyndon-johnson-wrapper .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");   filter:gray;   -webkit-filter:grayscale(100%)}.eg-lyndon-johnson-wrapper:hover .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='1 0 0 0 0,0 1 0 0 0,0 0 1 0 0,0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");  -webkit-filter:grayscale(0%)}.esg-overlay.eg-ronald-reagan-container{background:-moz-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-webkit-gradient(linear,left top,left bottom,color-stop(50%,rgba(0,0,0,0)),color-stop(99%,rgba(0,0,0,0.83)),color-stop(100%,rgba(0,0,0,0.85))); background:-webkit-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-o-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-ms-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:linear-gradient(to bottom,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#00000000',endColorstr='#d9000000',GradientType=0 )}.eg-georgebush-wrapper .esg-entry-cover{background:-moz-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-webkit-gradient(linear,left top,left bottom,color-stop(50%,rgba(0,0,0,0)),color-stop(99%,rgba(0,0,0,0.83)),color-stop(100%,rgba(0,0,0,0.85))); background:-webkit-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-o-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-ms-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:linear-gradient(to bottom,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#00000000',endColorstr='#d9000000',GradientType=0 )}.eg-jefferson-wrapper{-webkit-border-radius:5px !important; -moz-border-radius:5px !important; border-radius:5px !important; -webkit-mask-image:url(data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAA5JREFUeNpiYGBgAAgwAAAEAAGbA+oJAAAAAElFTkSuQmCC) !important}.eg-monroe-element-1{text-shadow:0px 1px 3px rgba(0,0,0,0.1)}.eg-lyndon-johnson-wrapper .esg-entry-cover{background:-moz-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-webkit-gradient(radial,center center,0px,center center,100%,color-stop(0%,rgba(0,0,0,0.35)),color-stop(96%,rgba(18,18,18,0)),color-stop(100%,rgba(19,19,19,0))); background:-webkit-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-o-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-ms-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:radial-gradient(ellipse at center,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#59000000',endColorstr='#00131313',GradientType=1 )}.eg-wilbert-wrapper .esg-entry-cover{background:-moz-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-webkit-gradient(radial,center center,0px,center center,100%,color-stop(0%,rgba(0,0,0,0.35)),color-stop(96%,rgba(18,18,18,0)),color-stop(100%,rgba(19,19,19,0))); background:-webkit-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-o-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:-ms-radial-gradient(center,ellipse cover,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); background:radial-gradient(ellipse at center,rgba(0,0,0,0.35) 0%,rgba(18,18,18,0) 96%,rgba(19,19,19,0) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#59000000',endColorstr='#00131313',GradientType=1 )}.eg-wilbert-wrapper .esg-media-poster{-webkit-transition:0.4s ease-in-out;  -moz-transition:0.4s ease-in-out;  -o-transition:0.4s ease-in-out;  transition:0.4s ease-in-out;  filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");   filter:gray;   -webkit-filter:grayscale(100%)}.eg-wilbert-wrapper:hover .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='1 0 0 0 0,0 1 0 0 0,0 0 1 0 0,0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");  -webkit-filter:grayscale(0%)}.eg-phillie-element-3:after{content:\" \";width:0px;height:0px;border-style:solid;border-width:5px 5px 0 5px;border-color:#000 transparent transparent transparent;left:50%;margin-left:-5px; bottom:-5px; position:absolute}.eg-howardtaft-wrapper .esg-media-poster,.eg-howardtaft-wrapper .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='1 0 0 0 0,0 1 0 0 0,0 0 1 0 0,0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");  -webkit-filter:grayscale(0%)}.eg-howardtaft-wrapper:hover .esg-media-poster,.eg-howardtaft-wrapper:hover .esg-media-poster{filter:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg'><filter id='grayscale'><feColorMatrix type='matrix' values='0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0.3333 0.3333 0.3333 0 0 0 0 0 1 0'\/><\/filter><\/svg>#grayscale\");   filter:gray;   -webkit-filter:grayscale(100%)}.myportfolio-container .added_to_cart.wc-forward{font-family:\"Open Sans\"; font-size:13px; color:#fff; margin-top:10px}.esgbox-title.esgbox-title-outside-wrap{font-size:15px; font-weight:700; text-align:center}.esgbox-title.esgbox-title-inside-wrap{padding-bottom:10px; font-size:15px; font-weight:700; text-align:center}.esg-content.eg-twitterstream-element-33-a{display:inline-block}.eg-twitterstream-element-35{word-break:break-all}.esg-overlay.eg-twitterstream-container{background:-moz-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-webkit-gradient(linear,left top,left bottom,color-stop(50%,rgba(0,0,0,0)),color-stop(99%,rgba(0,0,0,0.83)),color-stop(100%,rgba(0,0,0,0.85))); background:-webkit-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-o-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-ms-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:linear-gradient(to bottom,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#00000000',endColorstr='#d9000000',GradientType=0 )}.esg-content.eg-facebookstream-element-33-a{display:inline-block}.eg-facebookstream-element-0{word-break:break-all}.esg-overlay.eg-flickrstream-container{background:-moz-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-webkit-gradient(linear,left top,left bottom,color-stop(50%,rgba(0,0,0,0)),color-stop(99%,rgba(0,0,0,0.83)),color-stop(100%,rgba(0,0,0,0.85))); background:-webkit-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-o-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:-ms-linear-gradient(top,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); background:linear-gradient(to bottom,rgba(0,0,0,0) 50%,rgba(0,0,0,0.83) 99%,rgba(0,0,0,0.85) 100%); filter:progid:DXImageTransform.Microsoft.gradient( startColorstr='#00000000',endColorstr='#d9000000',GradientType=0 )}<\/style>\n<style type=\"text\/css\">.minimal-light .navigationbuttons,.minimal-light .esg-pagination,.minimal-light .esg-filters{text-align:center}.minimal-light .esg-filterbutton,.minimal-light .esg-navigationbutton,.minimal-light .esg-sortbutton,.minimal-light .esg-cartbutton a{color:#999; margin-right:5px; cursor:pointer; padding:0px 16px; border:1px solid #e5e5e5; line-height:38px; border-radius:5px; -moz-border-radius:5px; -webkit-border-radius:5px; font-size:12px; font-weight:700; font-family:\"Open Sans\",sans-serif; display:inline-block; background:#fff; margin-bottom:5px}.minimal-light .esg-navigationbutton *{color:#999}.minimal-light .esg-navigationbutton{padding:0px 16px}.minimal-light .esg-pagination-button:last-child{margin-right:0}.minimal-light .esg-left,.minimal-light .esg-right{padding:0px 11px}.minimal-light .esg-sortbutton-wrapper,.minimal-light .esg-cartbutton-wrapper{display:inline-block}.minimal-light .esg-sortbutton-order,.minimal-light .esg-cartbutton-order{display:inline-block;  vertical-align:top;  border:1px solid #e5e5e5;  width:40px;  line-height:38px;  border-radius:0px 5px 5px 0px;  -moz-border-radius:0px 5px 5px 0px;  -webkit-border-radius:0px 5px 5px 0px;  font-size:12px;  font-weight:700;  color:#999;  cursor:pointer;  background:#fff}.minimal-light .esg-cartbutton{color:#333; cursor:default !important}.minimal-light .esg-cartbutton .esgicon-basket{color:#333;   font-size:15px;   line-height:15px;   margin-right:10px}.minimal-light .esg-cartbutton-wrapper{cursor:default !important}.minimal-light .esg-sortbutton,.minimal-light .esg-cartbutton{display:inline-block; position:relative; cursor:pointer; margin-right:0px; border-right:none; border-radius:5px 0px 0px 5px; -moz-border-radius:5px 0px 0px 5px; -webkit-border-radius:5px 0px 0px 5px}.minimal-light .esg-navigationbutton:hover,.minimal-light .esg-filterbutton:hover,.minimal-light .esg-sortbutton:hover,.minimal-light .esg-sortbutton-order:hover,.minimal-light .esg-cartbutton a:hover,.minimal-light .esg-filterbutton.selected{background-color:#fff;   border-color:#bbb;   color:#333;   box-shadow:0px 3px 5px 0px rgba(0,0,0,0.13)}.minimal-light .esg-navigationbutton:hover *{color:#333}.minimal-light .esg-sortbutton-order.tp-desc:hover{border-color:#bbb; color:#333; box-shadow:0px -3px 5px 0px rgba(0,0,0,0.13) !important}.minimal-light .esg-filter-checked{padding:1px 3px;  color:#cbcbcb;  background:#cbcbcb;  margin-left:7px;  font-size:9px;  font-weight:300;  line-height:9px;  vertical-align:middle}.minimal-light .esg-filterbutton.selected .esg-filter-checked,.minimal-light .esg-filterbutton:hover .esg-filter-checked{padding:1px 3px 1px 3px;  color:#fff;  background:#000;  margin-left:7px;  font-size:9px;  font-weight:300;  line-height:9px;  vertical-align:middle}<\/style>\n<style type=\"text\/css\">.eg-deja-row-element-1{font-size:14px; line-height:20px; color:#ffffff; font-weight:500; padding:3px 10px 3px 10px ; border-radius:5px 5px 5px 5px ; background:#d2005e; height:auto; width:auto; z-index:2 !important; display:block; font-family:\"Raleway\"; text-transform:uppercase}.eg-deja-row-element-4{font-size:16px !important; line-height:20px !important; color:#0c2340 !important; font-weight:700 !important; padding:0px 0px 0px 0px !important; border-radius:0px 0px 0px 0px !important; background:transparent !important; z-index:2 !important; display:block; text-transform:uppercase !important}.eg-deja-row-element-2{font-size:13px; line-height:20px; color:#0c2340; font-weight:400; display:inline-block; float:left; clear:both; margin:0px 0px 15px 70px ; padding:0px 0px 0px 0px ; border-radius:0px 0px 0px 0px ; background:transparent; position:relative; z-index:2 !important; font-family:\"Raleway\"; text-transform:uppercase}<\/style>\n<style type=\"text\/css\">.eg-deja-row-element-1:hover{font-size:17px; line-height:24px; color:#ffffff; font-weight:500; border-radius:3px 3px 3px 3px ; background:#e31c79; font-family:\"Raleway\"; text-transform:uppercase}<\/style>\n<style type=\"text\/css\">.eg-deja-row-element-1-a{display:inline-block; float:left; clear:none; margin:-0px 0px 0px 20px ; position:absolute; top:0px; left:-15px}<\/style>\n<style type=\"text\/css\">.eg-deja-row-element-4-a{display:inline-block !important; float:left !important; clear:both !important; margin:1px 0px 0px 70px !important; position:relative !important}<\/style>\n<style type=\"text\/css\">.eg-deja-row-container{background:transparent}<\/style>\n<style type=\"text\/css\">.eg-deja-row-content{background:transparent; padding:0px 0px 0px 0px; border-width:0px 0px 0px 0px; border-radius:0px 0px 0px 0px; border-color:transparent; border-style:none; text-align:left}<\/style>\n<style type=\"text\/css\">.esg-grid .mainul li.eg-deja-row-wrapper{background:transparent; padding:0px 0px 0px 0px; border-width:0px 0px 0px 0px; border-radius:0px 0px 0px 0px; border-color:transparent; border-style:none}<\/style>\n<style type=\"text\/css\">.esg-grid .mainul li.eg-deja-row-wrapper .esg-media-poster{background-size:cover; background-position:center center; background-repeat:repeat}<\/style>\n<!-- THE ESSENTIAL GRID 3.0.16 POST -->\n\n<article class=\"myportfolio-container minimal-light esg-entry-skin-deja-row source_type_post\" id=\"esg-grid-1-custom_post-1-wrap\">\n\n   <div id=\"esg-grid-1-custom_post-1\" class=\"esg-grid\" style=\"background: transparent;padding: 0px 0px 0px 0px ; box-sizing:border-box; -moz-box-sizing:border-box; -webkit-box-sizing:border-box; display:none\">\n<ul>\n<li id=\"eg-1-post-id-33316_5359\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-farmaceutico-e-life-sciences filter-giulia-beneduci-it filter-nella-stampa filter-responsabilita-da-prodotto-sicurezza filter-roberto-jacchia-it filter-silvia-bolognani-it filter-silvia-doria-it eg-deja-row-wrapper eg-post-id-33316\" data-date=\"1783950729\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-33316 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-33316\" href=\"https:\/\/www.dejalex.com\/it\/2026\/07\/de-berti-jacchia-assiste-omnivision-il-tribunale-di-milano-esclude-la-concorrenza-sleale-e-conferma-il-rigetto-del-reclamo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-33316 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-33316\" href=\"https:\/\/www.dejalex.com\/it\/2026\/07\/de-berti-jacchia-assiste-omnivision-il-tribunale-di-milano-esclude-la-concorrenza-sleale-e-conferma-il-rigetto-del-reclamo\/\" target=\"_self\">DE BERTI JACCHIA ASSISTE OMNIVISION: IL TRIBUNALE DI MILANO ESCLUDE LA CONCORRENZA SLEALE E CONFERMA IL RIGETTO DEL RECLAMO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-33316 eg-deja-row-element-2\">OmniVision \u00e8 stata assistita da Roberto Angelo Jacchia, Silvia Doria, Giulia Beneduci e Silvia Bolognani<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-33230_509\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-it-tmt-it filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-33230\" data-date=\"1782133129\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-33230 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-33230\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/a-che-punto-siamo-con-leuropean-biotech-act\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">22<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-33230 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-33230\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/a-che-punto-siamo-con-leuropean-biotech-act\/\" target=\"_self\">A CHE PUNTO SIAMO CON L\u2019EUROPEAN BIOTECH ACT?<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-33230 eg-deja-row-element-2\">L'approfondimento a firma di Roberto A. Jacchia e Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-33213_3749\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-33213\" data-date=\"1781007253\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-33213 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-33213\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/la-corte-di-giustizia-si-pronuncia-sulla-verifica-della-qualifica-di-dispositivo-medico-quando-il-fabbricante-ha-apposto-sullo-stesso-la-marcatura-ce-come-macchina\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">09<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-33213 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-33213\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/la-corte-di-giustizia-si-pronuncia-sulla-verifica-della-qualifica-di-dispositivo-medico-quando-il-fabbricante-ha-apposto-sullo-stesso-la-marcatura-ce-come-macchina\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA VERIFICA DELLA QUALIFICA DI \u201cDISPOSITIVO MEDICO\u201d QUANDO IL FABBRICANTE HA APPOSTO SULLO STESSO LA MARCATURA CE COME \u201cMACCHINA\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-33213 eg-deja-row-element-2\">L'approfondimento a firma di Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-33152_9505\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa-imprese-e-insolvenza eg-deja-row-wrapper eg-post-id-33152\" data-date=\"1780490414\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-33152 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-33152\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/farmaci-per-il-trattamento-della-sclerosi-multipla-lagcm-avvia-unistruttoria-nei-confronti-di-biogen-per-un-presunto-abuso-di-posizione-dominante-in-un-mercato-contiguo-mediante-pra\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">03<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-33152 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-33152\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/farmaci-per-il-trattamento-della-sclerosi-multipla-lagcm-avvia-unistruttoria-nei-confronti-di-biogen-per-un-presunto-abuso-di-posizione-dominante-in-un-mercato-contiguo-mediante-pra\/\" target=\"_self\">FARMACI PER IL TRATTAMENTO DELLA SCLEROSI MULTIPLA. L\u2019AGCM AVVIA UN\u2019ISTRUTTORIA NEI CONFRONTI DI BIOGEN PER UN PRESUNTO ABUSO DI POSIZIONE DOMINANTE IN UN MERCATO CONTIGUO MEDIANTE PRATICHE DI BUNDLING<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-33152 eg-deja-row-element-2\">L'approfondimento a firma di Roberto A. Jacchia e Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-33147_5506\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-33147\" data-date=\"1780489643\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-33147 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-33147\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-divieto-di-vendita-a-distanza-al-pubblico-mediante-i-servizi-della-societa-dellinformazione-di-una-categoria-di-medicinali-n\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">03<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-33147 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-33147\" href=\"https:\/\/www.dejalex.com\/it\/2026\/06\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-divieto-di-vendita-a-distanza-al-pubblico-mediante-i-servizi-della-societa-dellinformazione-di-una-categoria-di-medicinali-n\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL DIVIETO DI VENDITA A DISTANZA AL PUBBLICO, MEDIANTE I SERVIZI DELLA SOCIET\u00c0 DELL\u2019INFORMAZIONE, DI UNA CATEGORIA DI MEDICINALI NON SOGGETTI A PRESCRIZIONE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-33147 eg-deja-row-element-2\">L'approfondimento a firma di Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-32764_1662\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-32764\" data-date=\"1777389208\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-32764 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-32764\" href=\"https:\/\/www.dejalex.com\/it\/2026\/04\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-competenza-dei-giudici-nazionali-a-verificare-le-condizioni-per-il-rilascio-di-unautorizzazione-allimmissione-in-co\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-32764 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-32764\" href=\"https:\/\/www.dejalex.com\/it\/2026\/04\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-competenza-dei-giudici-nazionali-a-verificare-le-condizioni-per-il-rilascio-di-unautorizzazione-allimmissione-in-co\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA COMPETENZA DEI GIUDICI NAZIONALI A VERIFICARE LE CONDIZIONI PER IL RILASCIO DI UN\u2019AUTORIZZAZIONE ALL\u2019IMMISSIONE IN COMMERCIO DI UN MEDICINALE GENERICO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-32764 eg-deja-row-element-2\">L'approfondimento a firma di Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-32844_5101\" data-skin=\"deja-row\" class=\"filterall filter-david-maria-santoro-it filter-farmaceutico-e-life-sciences filter-nella-stampa filter-pubblicazioni eg-deja-row-wrapper eg-post-id-32844\" data-date=\"1775049705\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-32844 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-32844\" href=\"https:\/\/www.dejalex.com\/it\/2026\/04\/danno-da-farmaci-ecco-come-rintracciare-il-nesso-di-causalita\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">01<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-32844 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-32844\" href=\"https:\/\/www.dejalex.com\/it\/2026\/04\/danno-da-farmaci-ecco-come-rintracciare-il-nesso-di-causalita\/\" target=\"_self\">DANNO DA FARMACI: ECCO COME RINTRACCIARE IL NESSO DI CAUSALIT\u00c0<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-32844 eg-deja-row-element-2\">L'articolo a firma di David Maria Santoro su AboutPharma<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-32406_6183\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-32406\" data-date=\"1774274593\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-32406 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-32406\" href=\"https:\/\/www.dejalex.com\/it\/2026\/03\/la-corte-di-giustizia-si-pronuncia-sulla-normativa-nazionale-che-sottopone-i-medicinali-preparati-in-farmacia-in-base-alle-indicazioni-di-una-farmacopea-e-destinati-ad-essere-forniti-direttamente-ai\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-32406 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-32406\" href=\"https:\/\/www.dejalex.com\/it\/2026\/03\/la-corte-di-giustizia-si-pronuncia-sulla-normativa-nazionale-che-sottopone-i-medicinali-preparati-in-farmacia-in-base-alle-indicazioni-di-una-farmacopea-e-destinati-ad-essere-forniti-direttamente-ai\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA NORMATIVA NAZIONALE CHE SOTTOPONE I MEDICINALI PREPARATI IN FARMACIA IN BASE ALLE INDICAZIONI DI UNA FARMACOPEA, E DESTINATI AD ESSERE FORNITI DIRETTAMENTE AI RELATIVI PAZIENTI, AD UN OBBLIGO DI AUTORIZZAZIONE IN BASE AD UN CRITERIO NUMERICO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-32406 eg-deja-row-element-2\">L'approfondimento a firma di Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-32414_8456\" data-skin=\"deja-row\" class=\"filterall filter-andrea-terragni-it filter-antonella-terranova-it filter-benedetta-mazzotti-it filter-claudio-corba-colombo-it filter-farmaceutico-e-life-sciences filter-gaspare-roma-it filter-ma-it filter-nella-stampa filter-pietro-meda-it filter-tiziana-zona-it eg-deja-row-wrapper eg-post-id-32414\" data-date=\"1773671984\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-32414 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-32414\" href=\"https:\/\/www.dejalex.com\/it\/2026\/03\/de-berti-jacchia-con-olyos-group-nellacquisizione-di-somatoline-da-manetti-roberts\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">16<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-32414 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-32414\" href=\"https:\/\/www.dejalex.com\/it\/2026\/03\/de-berti-jacchia-con-olyos-group-nellacquisizione-di-somatoline-da-manetti-roberts\/\" target=\"_self\">DE BERTI JACCHIA CON OLYOS GROUP NELL\u2019ACQUISIZIONE DI SOMATOLINE DA MANETTI & ROBERTS<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-32414 eg-deja-row-element-2\">Olyos Group \u00e8 stato assistito da Claudio Corba Colombo, Antonella Terranova, Pietro Meda, Andrea Terragni, Tiziana Zona, Gaspare Roma e Benedetta Mazzotti.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-32083_4729\" data-skin=\"deja-row\" class=\"filterall filter-digital-tech-it filter-farmaceutico-e-life-sciences filter-nella-stampa eg-deja-row-wrapper eg-post-id-32083\" data-date=\"1762787615\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-32083 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-32083\" href=\"https:\/\/www.dejalex.com\/it\/2025\/11\/sanita-e-ia-la-responsabilita-medica-non-si-affievolisce\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">10<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-32083 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-32083\" href=\"https:\/\/www.dejalex.com\/it\/2025\/11\/sanita-e-ia-la-responsabilita-medica-non-si-affievolisce\/\" target=\"_self\">SANIT\u00c0 E IA, LA RESPONSABILIT\u00c0 MEDICA NON SI AFFIEVOLISCE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-32083 eg-deja-row-element-2\">Marco Stillo intervistato da ItaliaOggi\r\n<br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-31874_1674\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-31874\" data-date=\"1761665489\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-31874 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-31874\" href=\"https:\/\/www.dejalex.com\/it\/2025\/10\/accordi-pay-for-delay-la-corte-di-giustizia-respinge-il-ricorso-di-teva-e-cephalon\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-31874 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-31874\" href=\"https:\/\/www.dejalex.com\/it\/2025\/10\/accordi-pay-for-delay-la-corte-di-giustizia-respinge-il-ricorso-di-teva-e-cephalon\/\" target=\"_self\">ACCORDI PAY-FOR-DELAY. LA CORTE DI GIUSTIZIA RESPINGE IL RICORSO DI TEVA E CEPHALON<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-31874 eg-deja-row-element-2\">L'articolo a firma di Marco Stillo su Lexology<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-31984_8944\" data-skin=\"deja-row\" class=\"filterall filter-andrea-terragni-it filter-benedetta-mazzotti-it filter-claudio-corba-colombo-it filter-farmaceutico-e-life-sciences filter-francesca-zironi-it filter-giuseppe-cristiano-it filter-laura-bussoli-it filter-ma-it filter-nella-stampa filter-pietro-meda-it eg-deja-row-wrapper eg-post-id-31984\" data-date=\"1756902576\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-31984 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-31984\" href=\"https:\/\/www.dejalex.com\/it\/2025\/09\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-derinox\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">03<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-31984 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-31984\" href=\"https:\/\/www.dejalex.com\/it\/2025\/09\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-derinox\/\" target=\"_self\">DE BERTI JACCHIA CON LABORATORIO FARMACEUTICO SIT NELL\u2019ACQUISIZIONE DI DERINOX<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-31984 eg-deja-row-element-2\">Con un team guidato dal Partner Pietro Meda, lo Studio ha assistito SIT in tutte le fasi dell\u2019operazione<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-31624_4305\" data-skin=\"deja-row\" class=\"filterall filter-andrea-terragni-it filter-benedetta-mazzotti-it filter-claudio-corba-colombo-it filter-farmaceutico-e-life-sciences filter-francesca-zironi-it filter-giuseppe-cristiano-it filter-laura-bussoli-it filter-ma-it filter-nella-stampa filter-pietro-meda-it eg-deja-row-wrapper eg-post-id-31624\" data-date=\"1751539047\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-31624 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-31624\" href=\"https:\/\/www.dejalex.com\/it\/2025\/07\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-mizollen\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">03<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-31624 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-31624\" href=\"https:\/\/www.dejalex.com\/it\/2025\/07\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-mizollen\/\" target=\"_self\">DE BERTI JACCHIA CON LABORATORIO FARMACEUTICO SIT NELL\u2019ACQUISIZIONE DI MIZOLLEN<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-31624 eg-deja-row-element-2\">Con un team guidato dal Partner Pietro Meda, lo Studio ha assistito SIT in tutte le fasi dell\u2019operazione<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-31460_189\" data-skin=\"deja-row\" class=\"filterall filter-david-maria-santoro-it filter-farmaceutico-e-life-sciences filter-nella-stampa filter-pubblicazioni eg-deja-row-wrapper eg-post-id-31460\" data-date=\"1749113400\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-31460 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-31460\" href=\"https:\/\/www.dejalex.com\/it\/2025\/06\/risarcimento-da-danno-vaccinale-cura-metodologica-per-il-vaglio-del-nesso-di-causalita-materiale\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-31460 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-31460\" href=\"https:\/\/www.dejalex.com\/it\/2025\/06\/risarcimento-da-danno-vaccinale-cura-metodologica-per-il-vaglio-del-nesso-di-causalita-materiale\/\" target=\"_self\">RISARCIMENTO DA DANNO VACCINALE: CURA METODOLOGICA PER IL VAGLIO DEL NESSO DI CAUSALIT\u00c0 MATERIALE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-31460 eg-deja-row-element-2\">L'articolo a firma di David Maria Santoro su AssoCareNews<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-31076_4643\" data-skin=\"deja-row\" class=\"filterall filter-andrea-terragni-it filter-farmaceutico-e-life-sciences filter-francesca-zironi-it filter-laura-bussoli-it filter-ma-it filter-nella-stampa filter-pietro-meda-it eg-deja-row-wrapper eg-post-id-31076\" data-date=\"1743610951\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-31076 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-31076\" href=\"https:\/\/www.dejalex.com\/it\/2025\/04\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-dintoina\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">02<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-31076 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-31076\" href=\"https:\/\/www.dejalex.com\/it\/2025\/04\/de-berti-jacchia-con-laboratorio-farmaceutico-sit-nellacquisizione-di-dintoina\/\" target=\"_self\">DE BERTI JACCHIA CON LABORATORIO FARMACEUTICO SIT NELL\u2019ACQUISIZIONE DI DINTOINA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-31076 eg-deja-row-element-2\">Con un team guidato dal Partner Pietro Meda, lo Studio ha assistito SIT in tutte le fasi dell\u2019operazione<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30995_7807\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-30995\" data-date=\"1742999519\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30995 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30995\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/medicinali-critici-la-proposta-della-commissione-per-rendere-piu-resilienti-le-catene-di-approvvigionamento\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">26<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30995 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30995\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/medicinali-critici-la-proposta-della-commissione-per-rendere-piu-resilienti-le-catene-di-approvvigionamento\/\" target=\"_self\">MEDICINALI CRITICI. LA PROPOSTA DELLA COMMISSIONE PER RENDERE PI\u00d9 RESILIENTI LE CATENE DI APPROVVIGIONAMENTO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30995 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso, Protezione dei Dati e Cybersecurity<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30989_8754\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30989\" data-date=\"1742912796\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30989 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30989\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-nozione-di-azione-farmacologica\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">25<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30989 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30989\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-nozione-di-azione-farmacologica\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA NOZIONE DI \u201cAZIONE FARMACOLOGICA\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30989 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso, Protezione dei Dati e Cybersecurity<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30985_4278\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30985\" data-date=\"1741875656\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30985 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30985\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/la-corte-di-giustizia-si-pronuncia-sulla-nozione-di-pubblicita-dei-medicinali-e-sulle-azioni-pubblicitarie-realizzate-per-lacquisto-di-medicinali-indeterminati-soggetti-a-pr\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30985 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30985\" href=\"https:\/\/www.dejalex.com\/it\/2025\/03\/la-corte-di-giustizia-si-pronuncia-sulla-nozione-di-pubblicita-dei-medicinali-e-sulle-azioni-pubblicitarie-realizzate-per-lacquisto-di-medicinali-indeterminati-soggetti-a-pr\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA NOZIONE DI \u201cPUBBLICIT\u00c0 DEI MEDICINALI\u201d E SULLE AZIONI PUBBLICITARIE REALIZZATE PER L\u2019ACQUISTO DI MEDICINALI INDETERMINATI SOGGETTI A PRESCRIZIONE MEDICA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30985 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso, Protezione dei Dati e Cybersecurity<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30932_7760\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30932\" data-date=\"1739542269\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30932 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30932\" href=\"https:\/\/www.dejalex.com\/it\/2025\/02\/linee-guida-aifa-clinical-trials-studi-osservazionali\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">14<\/span>\n<span style=\"text-align: center;\">Feb<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30932 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30932\" href=\"https:\/\/www.dejalex.com\/it\/2025\/02\/linee-guida-aifa-clinical-trials-studi-osservazionali\/\" target=\"_self\">CLINICAL TRIALS E STUDI OSSERVAZIONALI. LE NUOVE LINEE GUIDA DELL\u2019AIFA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30932 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30734_1413\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30734\" data-date=\"1737632801\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30734 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30734\" href=\"https:\/\/www.dejalex.com\/it\/2025\/01\/certificati-protettivi-complementari-principi-attivi\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30734 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30734\" href=\"https:\/\/www.dejalex.com\/it\/2025\/01\/certificati-protettivi-complementari-principi-attivi\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE NOZIONI DI \u201cPRODOTTO PROTETTO DA UN BREVETTO DI BASE IN VIGORE\u201d E DI \u201cPRODOTTO OGGETTO DI UN CPC\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30734 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30450_5173\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-nella-stampa filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-30450\" data-date=\"1732632756\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30450 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30450\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/farmaci-orfani-studi-in-campo-per-la-cura-delle-malattie-rare\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">26<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30450 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30450\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/farmaci-orfani-studi-in-campo-per-la-cura-delle-malattie-rare\/\" target=\"_self\">FARMACI ORFANI, STUDI IN CAMPO PER LA CURA DELLE MALATTIE RARE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30450 eg-deja-row-element-2\"><br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30558_8476\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30558\" data-date=\"1732285412\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30558 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30558\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/accordi-pay-for-delay-corte-giustizia-perindopril\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">22<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30558 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30558\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/accordi-pay-for-delay-corte-giustizia-perindopril\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SUGLI ACCORDI PAY-FOR-DELAY NEL CASO DEL PERINDOPRIL<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30558 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Science, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30408_7097\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30408\" data-date=\"1731073181\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30408 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30408\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/medicinali-orfani-beneficio-significativo-superiorita-clinica\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">08<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30408 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30408\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/medicinali-orfani-beneficio-significativo-superiorita-clinica\/\" target=\"_self\">MEDICINALI ORFANI. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE NOZIONI DI \u201cBENEFICIO SIGNIFICATIVO\u201d E \u201cSUPERIORIT\u00c0 CLINICA\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30408 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30350_6887\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30350\" data-date=\"1730886269\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30350 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30350\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/commissione-ue-sanziona-teva-abuso-posizione-dominante-sclerosi-multipla\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">06<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30350 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30350\" href=\"https:\/\/www.dejalex.com\/it\/2024\/11\/commissione-ue-sanziona-teva-abuso-posizione-dominante-sclerosi-multipla\/\" target=\"_self\">LA COMMISSIONE SANZIONA LA TEVA PER ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI CONTRO LA SCLEROSI MULTIPLA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30350 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30396_8662\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-david-maria-santoro-it filter-farmaceutico-e-life-sciences filter-nella-stampa eg-deja-row-wrapper eg-post-id-30396\" data-date=\"1729769799\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30396 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30396\" href=\"https:\/\/www.dejalex.com\/it\/2024\/10\/nuovo-risultato-favorevole-per-glaxosmithkline-sulla-responsabilita-da-prodotto\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30396 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30396\" href=\"https:\/\/www.dejalex.com\/it\/2024\/10\/nuovo-risultato-favorevole-per-glaxosmithkline-sulla-responsabilita-da-prodotto\/\" target=\"_self\">NUOVO RISULTATO FAVOREVOLE PER GLAXOSMITHKLINE SULLA RESPONSABILIT\u00c0 DA PRODOTTO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30396 eg-deja-row-element-2\">GlaxoSmithKline S.p.A. e altre societ\u00e0 collegate, tutte appartenenti all\u2019omonimo gruppo farmaceutico anglosassone, assistite da\u00a0De Berti Jacchia\u00a0con il partner David Maria Santoro, hanno visto riconosciuto il fondamento delle loro ragioni anche nel secondo grado<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30391_6418\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-30391\" data-date=\"1728904408\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30391 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30391\" href=\"https:\/\/www.dejalex.com\/it\/2024\/10\/certificato-protettivo-complementare-prima-autorizzazione-aic\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">14<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30391 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30391\" href=\"https:\/\/www.dejalex.com\/it\/2024\/10\/certificato-protettivo-complementare-prima-autorizzazione-aic\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULL\u2019AIC DA CONSIDERARE COME PRIMA A SOSTEGNO DI UNA DOMANDA DI CERTIFICATO PROTETTIVO COMPLEMENTARE PER UN PRODOTTO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30391 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-30051_5059\" data-skin=\"deja-row\" class=\"filterall filter-automotive-it filter-contenzioso filter-farmaceutico-e-life-sciences filter-francesca-zironi-it filter-ma-it filter-media-e-intrattenimento filter-moda-e-lusso filter-nella-stampa filter-pietro-meda-it filter-roberto-jacchia-it filter-tempo-libero-sport-sponsorizzazioni-e-turismo eg-deja-row-wrapper eg-post-id-30051\" data-date=\"1721034765\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-30051 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-30051\" href=\"https:\/\/www.dejalex.com\/it\/2024\/07\/pietro-meda-nuovo-socio-in-de-berti-jacchia\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">15<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-30051 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-30051\" href=\"https:\/\/www.dejalex.com\/it\/2024\/07\/pietro-meda-nuovo-socio-in-de-berti-jacchia\/\" target=\"_self\">PIETRO MEDA NUOVO SOCIO IN DE BERTI JACCHIA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-30051 eg-deja-row-element-2\">Pietro Meda, avvocato cassazionista esperto in diritto societario ed M&A, con particolare focus nei settori farmaceutico, real estate, automotive ed e-sports, entra in De Berti Jacchia in qualit\u00e0 di partner presso la sede di Milano.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29813_6338\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-29813\" data-date=\"1718296662\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29813 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29813\" href=\"https:\/\/www.dejalex.com\/it\/2024\/06\/rilascio-cpc-medicinali-ag-emiliou\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29813 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29813\" href=\"https:\/\/www.dejalex.com\/it\/2024\/06\/rilascio-cpc-medicinali-ag-emiliou\/\" target=\"_self\">MEDICINALI PER USO UMANO. L\u2019AG EMILIOU SI PRONUNCIA SUI CRITERI PER LA VALUTAZIONE DELLE CONDIZIONI DI RILASCIO DI UN CPC<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29813 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso,  Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29588_1352\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-29588\" data-date=\"1714403364\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29588 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29588\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/sentenza-ag-emiliou-analisi-implicazioni-illlumina-grail\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">29<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29588 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29588\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/sentenza-ag-emiliou-analisi-implicazioni-illlumina-grail\/\" target=\"_self\">GRAIL\/ILLUMINA. L\u2019AG EMILIOU SI PRONUNCIA SULLA SENTENZA DEL TRIBUNALE DELL\u2019UNIONE EUROPEA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29588 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29540_7653\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-29540\" data-date=\"1713454241\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29540 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29540\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/commissione-approva-cessione-grail-ripristino-concorrenza-mercato-ngs\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">18<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29540 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29540\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/commissione-approva-cessione-grail-ripristino-concorrenza-mercato-ngs\/\" target=\"_self\">LA COMMISSIONE APPROVA LA CESSIONE DELLA GRAIL DA PARTE DELLA ILLUMINA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29540 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29475_7433\" data-skin=\"deja-row\" class=\"filterall filter-antonella-terranova-it filter-arbitrato-e-adr filter-contenzioso filter-david-maria-santoro-it filter-diritto-del-lavoro-e-previdenza filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-gaspare-roma-it filter-guido-callegari-it filter-maria-cristina-franchini-it filter-michelangelo-cicogna-it filter-nella-stampa filter-premi filter-proprieta-intellettuale filter-roberto-jacchia-it filter-societario-e-commerciale eg-deja-row-wrapper eg-post-id-29475\" data-date=\"1712308936\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29475 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29475\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/leaders-league-ranked-firm-2024\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29475 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29475\" href=\"https:\/\/www.dejalex.com\/it\/2024\/04\/leaders-league-ranked-firm-2024\/\" target=\"_self\">LEADERS LEAGUE: RANKED FIRM 2024<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29475 eg-deja-row-element-2\"><br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29305_2814\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-29305\" data-date=\"1709721748\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29305 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29305\" href=\"https:\/\/www.dejalex.com\/it\/2024\/03\/corte-giustizia-ue-vendita-online-medicinali\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">06<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29305 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29305\" href=\"https:\/\/www.dejalex.com\/it\/2024\/03\/corte-giustizia-ue-vendita-online-medicinali\/\" target=\"_self\">VENDITA ONLINE DI MEDICINALI NON SOGGETTI A PRESCRIZIONE. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE CONDIZIONI ALLE QUALI UNO STATO MEMBRO PU\u00d2 VIETARE UN SERVIZIO CHE METTE IN CONTATTO FARMACISTI E CLIENTI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29305 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-29296_1117\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-david-maria-santoro-it filter-farmaceutico-e-life-sciences filter-nella-stampa eg-deja-row-wrapper eg-post-id-29296\" data-date=\"1709633800\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-29296 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-29296\" href=\"https:\/\/www.dejalex.com\/it\/2024\/03\/responsabilita-da-farmaco-de-berti-jacchia-vince-ancora-per-glaxosmithkline\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-29296 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-29296\" href=\"https:\/\/www.dejalex.com\/it\/2024\/03\/responsabilita-da-farmaco-de-berti-jacchia-vince-ancora-per-glaxosmithkline\/\" target=\"_self\">RESPONSABILIT\u00c0 DA FARMACO: DE BERTI JACCHIA VINCE ANCORA PER GLAXOSMITHKLINE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-29296 eg-deja-row-element-2\">Anche davanti alla Corte d\u2019Appello, la difesa di\u00a0GlaxoSmithKline spa\u00a0e della sua collegata\u00a0SmithKline Beecham plc, coordinati dal Responsabile Affari Legali di GlaxoSmithKline spa,\u00a0Andrea de Min, era affidata a\u00a0David Maria Santoro, partner di\u00a0De Berti Jacchia.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-28688_51\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-28688\" data-date=\"1705400355\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-28688 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-28688\" href=\"https:\/\/www.dejalex.com\/it\/2024\/01\/corte-giustizia-ue-risarcimento-danni-misure-provvisorie-medicinali-mylan-gilead\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">16<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-28688 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-28688\" href=\"https:\/\/www.dejalex.com\/it\/2024\/01\/corte-giustizia-ue-risarcimento-danni-misure-provvisorie-medicinali-mylan-gilead\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE MISURE PROVVISORIE ORDINATE SULLA BASE DI UN CPC E SULLA LORO SUCCESSIVA REVOCA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-28688 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-28550_9066\" data-skin=\"deja-row\" class=\"filterall filter-antonella-terranova-it filter-diritto-amministrativo-e-pubblico filter-farmaceutico-e-life-sciences filter-nella-stampa filter-pubblicazioni eg-deja-row-wrapper eg-post-id-28550\" data-date=\"1703153030\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-28550 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-28550\" href=\"https:\/\/www.dejalex.com\/it\/2023\/12\/payback-sui-dispositivi-il-difficile-rapporto-con-la-costituzione\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">21<\/span>\n<span style=\"text-align: center;\">Dic<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-28550 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-28550\" href=\"https:\/\/www.dejalex.com\/it\/2023\/12\/payback-sui-dispositivi-il-difficile-rapporto-con-la-costituzione\/\" target=\"_self\">PAYBACK SUI DISPOSITIVI: IL DIFFICILE RAPPORTO CON LA COSTITUZIONE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-28550 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Amministrativo e Pubblico, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-28486_8676\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-28486\" data-date=\"1702572095\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-28486 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-28486\" href=\"https:\/\/www.dejalex.com\/it\/2023\/12\/pronunciamento-corte-giustizia-importazione-prodotti-fitosanitari\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">14<\/span>\n<span style=\"text-align: center;\">Dic<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-28486 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-28486\" href=\"https:\/\/www.dejalex.com\/it\/2023\/12\/pronunciamento-corte-giustizia-importazione-prodotti-fitosanitari\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SULL\u2019IMPORTAZIONE DI UN PRODOTTO SANITARIO IN UNO STATO MEMBRO SULLA BASE DI UN PERMESSO DI COMMERCIO PARALLELO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-28486 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-28353_8634\" data-skin=\"deja-row\" class=\"filterall filter-coronavirus-it filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-protezione-dei-dati-e-cybersecurity filter-pubblicazioni eg-deja-row-wrapper eg-post-id-28353\" data-date=\"1700736785\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-28353 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-28353\" href=\"https:\/\/www.dejalex.com\/it\/2023\/11\/corte-giustizia-ue-verifica-validita-certificati-covid-app-mobile\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-28353 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-28353\" href=\"https:\/\/www.dejalex.com\/it\/2023\/11\/corte-giustizia-ue-verifica-validita-certificati-covid-app-mobile\/\" target=\"_self\">DATI PERSONALI. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA VERIFICA DELLA VALIDIT\u00c0 DEI \u201cCERTIFICATI COVID DIGITALI DELL\u2019UE\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-28353 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Protezione dei Dati e Cybersecurity, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27992_3319\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-27992\" data-date=\"1698335849\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27992 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27992\" href=\"https:\/\/www.dejalex.com\/it\/2023\/10\/cartello-farmaceutico-commissione-sanzioni\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">26<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27992 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27992\" href=\"https:\/\/www.dejalex.com\/it\/2023\/10\/cartello-farmaceutico-commissione-sanzioni\/\" target=\"_self\">CARTELLO NEL SETTORE FARMACEUTICO. LA COMMISSIONE SANZIONA 5 IMPRESE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27992 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27947_3539\" data-skin=\"deja-row\" class=\"filterall filter-antonella-terranova-it filter-arbitrato-e-adr filter-automotive-it filter-contenzioso filter-construction-it filter-diritto-della-crisi-di-impresa-e-ristrutturazione-del-debito filter-farmaceutico-e-life-sciences filter-it-tmt-it filter-luca-pescatore-it filter-nella-stampa filter-roberto-jacchia-it filter-societario-e-commerciale eg-deja-row-wrapper eg-post-id-27947\" data-date=\"1697445329\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27947 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27947\" href=\"https:\/\/www.dejalex.com\/it\/2023\/10\/luca-pescatore-nuovo-partner-di-de-berti-jacchia\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">16<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27947 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27947\" href=\"https:\/\/www.dejalex.com\/it\/2023\/10\/luca-pescatore-nuovo-partner-di-de-berti-jacchia\/\" target=\"_self\">LUCA PESCATORE NUOVO PARTNER DI DE BERTI JACCHIA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27947 eg-deja-row-element-2\">Luca Pescatore\u00a0fa il suo ingresso in De Berti Jacchia in qualit\u00e0 di partner nella sede di Roma.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27658_4945\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-27658\" data-date=\"1690555647\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27658 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27658\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/raccomandazioni-antibiotici-invernali-ue-infezioni-respiratorie\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27658 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27658\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/raccomandazioni-antibiotici-invernali-ue-infezioni-respiratorie\/\" target=\"_self\">NUOVE RACCOMANDAZIONI SUGLI ANTIBIOTICI. L\u2019UNIONE EUROPEA SI PREPARA ALL\u2019INVERNO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27658 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27665_9377\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-27665\" data-date=\"1690469790\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27665 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27665\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/sanzione-acquisizione-grail-illumina-obbligo-standstill\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">27<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27665 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27665\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/sanzione-acquisizione-grail-illumina-obbligo-standstill\/\" target=\"_self\">CALA IL SIPARIO SULL\u2019ACQUISIZIONE GRAIL\/ILLUMINA. LA COMMISSIONE SANZIONA LE DUE IMPRESE PER AVER VIOLATO L\u2019OBBLIGO DI STANDSTILL<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27665 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciencess, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27606_3023\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-agro-alimentare filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-27606\" data-date=\"1690186742\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27606 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27606\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/sentenza-c760-21-distinzione-alimenti-fini-medici-speciali-medicinali-integratori-alimentari-corte-di-giustizia-ue\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27606 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27606\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/sentenza-c760-21-distinzione-alimenti-fini-medici-speciali-medicinali-integratori-alimentari-corte-di-giustizia-ue\/\" target=\"_self\">ALIMENTI A FINI MEDICI SPECIALI, MEDICINALI ED INTEGRATORI ALIMENTARI RIVISITATI IN UNA RECENTE SENTENZA DELLA CORTE DI GIUSTIZIA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27606 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Agro-alimentare, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27616_4742\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-agro-alimentare filter-proprieta-intellettuale filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-27616\" data-date=\"1689755211\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27616 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27616\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/decisione-g-2-21-enlarged-board-appeal-epo-ammissibilita-dati-post-pubblicati-validita-certificati-protettivi-complementari\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">19<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27616 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27616\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/decisione-g-2-21-enlarged-board-appeal-epo-ammissibilita-dati-post-pubblicati-validita-certificati-protettivi-complementari\/\" target=\"_self\">LA DECISIONE G 2\/21 DELL\u2019 ENLARGED BOARD OF APPEAL DELL\u2019EPO. ALTEZZA INVENTIVA, PLAUSIBILIT\u00c0 E DATI POST-PUBBLICATI. IL CASO DEI CPC PER I MEDICINALI DI COMBINAZIONE E LE POSSIBILI DISCRASIE RISPETTO ALLA GIURISPRUDENZA DELLA CORTE DI GIUSTIZIA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27616 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Propriet\u00e0 Intellettuale, Agro-alimentare, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27399_6334\" data-skin=\"deja-row\" class=\"filterall filter-diritto-del-lavoro-e-previdenza filter-farmaceutico-e-life-sciences filter-gaspare-roma-it filter-nella-stampa filter-pubblicazioni eg-deja-row-wrapper eg-post-id-27399\" data-date=\"1689672145\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27399 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27399\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/le-persone-qualificate-nellindustria-farmaceutica-quadri-o-dirigenti\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">18<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27399 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27399\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/le-persone-qualificate-nellindustria-farmaceutica-quadri-o-dirigenti\/\" target=\"_self\">LE \u201cPERSONE QUALIFICATE\u201d NELL\u2019INDUSTRIA FARMACEUTICA: QUADRI O DIRIGENTI?<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27399 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto del Lavoro e Previdenza, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27378_3992\" data-skin=\"deja-row\" class=\"filterall filter-andrea-sonino-it filter-antonella-terranova-it filter-claudio-corba-colombo-it filter-contenzioso filter-david-maria-santoro-it filter-diritto-amministrativo-e-pubblico filter-bancario-e-mercati-finanziari filter-diritto-del-lavoro-e-previdenza filter-diritto-europeo-e-della-concorrenza filter-fabio-ferraro-it filter-farmaceutico-e-life-sciences filter-fiscale filter-gaspare-roma-it filter-giuseppe-cristiano-it filter-guido-callegari-it filter-ma-it filter-marco-frazzica-it filter-massimiliano-gazzo-it filter-michelangelo-cicogna-it filter-nella-stampa filter-premi filter-roberto-jacchia-it filter-societario-e-commerciale filter-tiziana-zona-it eg-deja-row-wrapper eg-post-id-27378\" data-date=\"1688994618\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27378 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27378\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/i-super-avvocati-e-i-super-studi-legali-corporate-2023\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">10<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27378 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27378\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/i-super-avvocati-e-i-super-studi-legali-corporate-2023\/\" target=\"_self\">I SUPER AVVOCATI E I SUPER STUDI LEGALI CORPORATE 2023<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27378 eg-deja-row-element-2\"><br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27368_2124\" data-skin=\"deja-row\" class=\"filterall filter-antonella-terranova-it filter-arbitrato-e-adr filter-contenzioso filter-david-maria-santoro-it filter-diritto-del-lavoro-e-previdenza filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-gaspare-roma-it filter-guido-callegari-it filter-maria-cristina-franchini-it filter-michelangelo-cicogna-it filter-nella-stampa filter-premi filter-proprieta-intellettuale filter-roberto-jacchia-it filter-societario-e-commerciale eg-deja-row-wrapper eg-post-id-27368\" data-date=\"1688652285\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27368 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27368\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/leaders-league-ranked-firm-2023\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">06<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27368 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27368\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/leaders-league-ranked-firm-2023\/\" target=\"_self\">LEADERS LEAGUE: RANKED FIRM 2023<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27368 eg-deja-row-element-2\"><br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27584_5466\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-27584\" data-date=\"1688562446\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27584 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27584\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/corte-di-giustizia-ue-sentenza-impresa-farmaceutica-prodotti-rivali\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27584 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27584\" href=\"https:\/\/www.dejalex.com\/it\/2023\/07\/corte-di-giustizia-ue-sentenza-impresa-farmaceutica-prodotti-rivali\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLE NOZIONI DI \u201cIMPRESA FARMACEUTICA\u201d E DI \u201cPRODOTTI RIVALI\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27584 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto europeo e della concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27020_2910\" data-skin=\"deja-row\" class=\"filterall filter-diritto-del-lavoro-e-previdenza filter-eventi filter-farmaceutico-e-life-sciences filter-gaspare-roma-it eg-deja-row-wrapper eg-post-id-27020\" data-date=\"1685003431\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27020 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27020\" href=\"https:\/\/www.dejalex.com\/it\/2023\/05\/qualified-person-ruolo-responsabilita-e-impatto-delle-novita-gmp-milan-may-25th-2023\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">25<\/span>\n<span style=\"text-align: center;\">Mag<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27020 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27020\" href=\"https:\/\/www.dejalex.com\/it\/2023\/05\/qualified-person-ruolo-responsabilita-e-impatto-delle-novita-gmp-milan-may-25th-2023\/\" target=\"_self\">QUALIFIED PERSON: RUOLO, RESPONSABILIT\u00c0 E IMPATTO DELLE NOVIT\u00c0 GMP - Milano, 25 maggio 2023<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27020 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-map-marker\" data-x-icon-s=\"&#xf041;\" aria-hidden=\"true\"><\/i> Milano<br \/>\r\n<i  class=\"x-icon x-icon-calendar\" data-x-icon-s=\"&#xf133;\" aria-hidden=\"true\"><\/i> 25 maggio 2023<br \/>\r\n<i  class=\"x-icon x-icon-user\" data-x-icon-s=\"&#xf007;\" aria-hidden=\"true\"><\/i> Gaspare Roma<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-27469_2703\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-27469\" data-date=\"1683904585\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-27469 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-27469\" href=\"https:\/\/www.dejalex.com\/it\/2023\/05\/legislazione-farmaceutica-proposte-commissione-pazienti-accesso-medicinali\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">12<\/span>\n<span style=\"text-align: center;\">Mag<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-27469 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-27469\" href=\"https:\/\/www.dejalex.com\/it\/2023\/05\/legislazione-farmaceutica-proposte-commissione-pazienti-accesso-medicinali\/\" target=\"_self\">LE PROPOSTE DELLA COMMISSIONE PER UNA LEGISLAZIONE FARMACEUTICA PI\u00d9 MODERNA E ADEGUATA ALLE ESIGENZE DEI PAZIENTI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-27469 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26628_31\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive eg-deja-row-wrapper eg-post-id-26628\" data-date=\"1679581953\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26628 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26628\" href=\"https:\/\/www.dejalex.com\/it\/2023\/03\/controllo-concentrazioni-imprese-corte-giustizia-ue-applicazione-regolamento-139-2004\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26628 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26628\" href=\"https:\/\/www.dejalex.com\/it\/2023\/03\/controllo-concentrazioni-imprese-corte-giustizia-ue-applicazione-regolamento-139-2004\/\" target=\"_self\">CONTROLLO DELLE CONCENTRAZIONI TRA IMPRESE. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULL\u2019APPLICAZIONE ESCLUSIVA DEL REGOLAMENTO 139\/2004 ALLE OPERAZIONI RIENTRANTI NELLA NOZIONE DI \u201cCONCENTRAZIONE\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26628 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Contenzioso, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26611_1490\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-26611\" data-date=\"1679479294\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26611 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26611\" href=\"https:\/\/www.dejalex.com\/it\/2023\/03\/la-corte-di-giustizia-si-pronuncia-sulla-decisione-dellema-recante-diniego-di-convalida-della-domanda-di-autorizzazione-allimmissione-in-commercio-di-un-medicinale-per-uso-umano\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">22<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26611 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26611\" href=\"https:\/\/www.dejalex.com\/it\/2023\/03\/la-corte-di-giustizia-si-pronuncia-sulla-decisione-dellema-recante-diniego-di-convalida-della-domanda-di-autorizzazione-allimmissione-in-commercio-di-un-medicinale-per-uso-umano\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA DECISIONE DELL\u2019EMA RECANTE DINIEGO DI CONVALIDA DELLA DOMANDA DI AUTORIZZAZIONE ALL\u2019IMMISSIONE IN COMMERCIO DI UN MEDICINALE PER USO UMANO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26611 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26379_8369\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-26379\" data-date=\"1675345442\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26379 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26379\" href=\"https:\/\/www.dejalex.com\/it\/2023\/02\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-classificazione-come-dispositivo-medico-o-medicinale\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">02<\/span>\n<span style=\"text-align: center;\">Feb<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26379 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26379\" href=\"https:\/\/www.dejalex.com\/it\/2023\/02\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-classificazione-come-dispositivo-medico-o-medicinale\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA CLASSIFICAZIONE COME \u201cDISPOSITIVO MEDICO\u201d O \u201cMEDICINALE\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26379 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Contenzioso, Diritto europeo e della concorrenza, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26346_2799\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-26346\" data-date=\"1674559405\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26346 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26346\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinal-products-for-human-use-the-court-of-justice-of-the-eu-rules-on-the-advertising-by-price-of-medicinal-products-not-subject-to-medical-prescription-and-not-reimbursed\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26346 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26346\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinal-products-for-human-use-the-court-of-justice-of-the-eu-rules-on-the-advertising-by-price-of-medicinal-products-not-subject-to-medical-prescription-and-not-reimbursed\/\" target=\"_self\">MEDICINAL PRODUCTS FOR HUMAN USE. THE COURT OF JUSTICE OF THE EU RULES ON THE ADVERTISING BY PRICE OF MEDICINAL PRODUCTS NOT SUBJECT TO MEDICAL PRESCRIPTION AND NOT REIMBURSED<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26346 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Eu and Competition, Litigation, Pharmaceuticals and Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26021_8496\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-26021\" data-date=\"1673519435\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26021 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26021\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-pubblicita-che-incoraggia-lacquisto-di-medicinali-non-soggetti-a-prescrizione-medica-e-non-rimborsabili-facendo-leva-sul-lor\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">12<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26021 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26021\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-pubblicita-che-incoraggia-lacquisto-di-medicinali-non-soggetti-a-prescrizione-medica-e-non-rimborsabili-facendo-leva-sul-lor\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA PUBBLICIT\u00c0 CHE INCORAGGIA L\u2019ACQUISTO DI MEDICINALI NON SOGGETTI A PRESCRIZIONE MEDICA E NON RIMBORSABILI FACENDO LEVA SUL LORO PREZZO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26021 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto europeo e della concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-26003_3074\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-26003\" data-date=\"1673433014\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-26003 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-26003\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-blocco-dei-prezzi-di-tutte-le-specialita-o-di-certe-loro-categorie\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">11<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-26003 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-26003\" href=\"https:\/\/www.dejalex.com\/it\/2023\/01\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-blocco-dei-prezzi-di-tutte-le-specialita-o-di-certe-loro-categorie\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL BLOCCO DEI PREZZI DI TUTTE LE SPECIALIT\u00c0 O DI CERTE LORO CATEGORIE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-26003 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto europeo e della concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25661_9313\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25661\" data-date=\"1669808242\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25661 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25661\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-diritto-del-titolare-del-marchio-di-un-medicinale-di-riferimento-e-di-quello-di-un-medicinale-generico-ad-opporsi-allimmission\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">30<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25661 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25661\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-diritto-del-titolare-del-marchio-di-un-medicinale-di-riferimento-e-di-quello-di-un-medicinale-generico-ad-opporsi-allimmission\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL DIRITTO DEL TITOLARE DEL MARCHIO DI UN MEDICINALE DI RIFERIMENTO E DI QUELLO DI UN MEDICINALE GENERICO AD OPPORSI ALL\u2019IMMISSIONE IN COMMERCIO DI QUEST\u2019ULTIMO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25661 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25668_8137\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25668\" data-date=\"1669729518\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25668 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25668\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-riapposizione-del-marchio-del-titolare-specifico-del-prodotto-ad-esclusione-degli-altri-marchi-o-segni-distintivi-figuranti-su-questo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">29<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25668 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25668\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sulla-riapposizione-del-marchio-del-titolare-specifico-del-prodotto-ad-esclusione-degli-altri-marchi-o-segni-distintivi-figuranti-su-questo\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA RIAPPOSIZIONE DEL MARCHIO DEL TITOLARE SPECIFICO DEL PRODOTTO AD ESCLUSIONE DEGLI ALTRI MARCHI O SEGNI DISTINTIVI FIGURANTI SU QUESTO IMBALLAGGIO ESTERNO D\u2019ORIGINE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25668 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25684_1754\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25684\" data-date=\"1669385384\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25684 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25684\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-riconfezionamento-in-un-nuovo-imballaggio-e-sulla-rietichettatura-di-medicinali-importati-parallelamente\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">25<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25684 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25684\" href=\"https:\/\/www.dejalex.com\/it\/2022\/11\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sul-riconfezionamento-in-un-nuovo-imballaggio-e-sulla-rietichettatura-di-medicinali-importati-parallelamente\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL RICONFEZIONAMENTO IN UN NUOVO IMBALLAGGIO E SULLA RIETICHETTATURA DI MEDICINALI IMPORTATI PARALLELAMENTE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25684 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25451_7952\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25451\" data-date=\"1666169340\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25451 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25451\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sugli-effetti-benefici-concreti-sulla-salute-umana\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">19<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25451 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25451\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/medicinali-per-uso-umano-la-corte-di-giustizia-si-pronuncia-sugli-effetti-benefici-concreti-sulla-salute-umana\/\" target=\"_self\">MEDICINALI PER USO UMANO. LA CORTE DI GIUSTIZIA SI PRONUNCIA SUGLI EFFETTI BENEFICI CONCRETI SULLA SALUTE UMANA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25451 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25746_1573\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25746\" data-date=\"1666021708\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25746 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25746\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-contro-la-sclerosi-multipla-la-commissione-invia-una-comunicazione-degli-addebiti-alla-teva\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">17<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25746 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25746\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-contro-la-sclerosi-multipla-la-commissione-invia-una-comunicazione-degli-addebiti-alla-teva\/\" target=\"_self\">ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI CONTRO LA SCLEROSI MULTIPLA. LA COMMISSIONE INVIA UNA COMUNICAZIONE DEGLI ADDEBITI ALLA TEVA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25746 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25755_9778\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-societa eg-deja-row-wrapper eg-post-id-25755\" data-date=\"1665676692\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25755 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25755\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-a-base-di-cdca-lautorita-garante-della-concorrenza-e-del-mercato-sanziona-il-gruppo-leadiant\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25755 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25755\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-a-base-di-cdca-lautorita-garante-della-concorrenza-e-del-mercato-sanziona-il-gruppo-leadiant\/\" target=\"_self\">ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI A BASE DI CDCA. L\u2019AUTORIT\u00c0 GARANTE DELLA CONCORRENZA E DEL MERCATO SANZIONA IL GRUPPO LEADIANT<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25755 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25819_6704\" data-skin=\"deja-row\" class=\"filterall filter-coronavirus-it filter-farmaceutico-e-life-sciences filter-proprieta-intellettuale filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-25819\" data-date=\"1664903152\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25819 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25819\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/lotta-al-coronavirus-le-proposte-della-commissione-per-i-prossimi-autunni-e-inverni\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">04<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25819 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25819\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/lotta-al-coronavirus-le-proposte-della-commissione-per-i-prossimi-autunni-e-inverni\/\" target=\"_self\">LOTTA AL CORONAVIRUS. LE PROPOSTE DELLA COMMISSIONE PER I PROSSIMI AUTUNNI E INVERNI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25819 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25437_7618\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-fabio-ferraro-it filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni eg-deja-row-wrapper eg-post-id-25437\" data-date=\"1664879544\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25437 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25437\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/la-commissione-pone-il-veto-allacquisizione-della-societa-grail\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">04<\/span>\n<span style=\"text-align: center;\">Ott<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25437 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25437\" href=\"https:\/\/www.dejalex.com\/it\/2022\/10\/la-commissione-pone-il-veto-allacquisizione-della-societa-grail\/\" target=\"_self\">LA COMMISSIONE PONE IL VETO ALL\u2019ACQUISIZIONE DELLA SOCIET\u00c0 GRAIL<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25437 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24933_8025\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24933\" data-date=\"1662021212\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24933 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24933\" href=\"https:\/\/www.dejalex.com\/it\/2022\/09\/nuovo-capitolo-nella-vicenda-grail-illumina-la-commissione-invia-una-nuova-comunicazione-degli-addebiti\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">01<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24933 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24933\" href=\"https:\/\/www.dejalex.com\/it\/2022\/09\/nuovo-capitolo-nella-vicenda-grail-illumina-la-commissione-invia-una-nuova-comunicazione-degli-addebiti\/\" target=\"_self\">NUOVO CAPITOLO NELLA VICENDA GRAIL\/ILLUMINA. LA COMMISSIONE INVIA UNA NUOVA COMUNICAZIONE DEGLI ADDEBITI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24933 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24958_6034\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24958\" data-date=\"1661763478\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24958 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24958\" href=\"https:\/\/www.dejalex.com\/it\/2022\/08\/sangue-tessuti-e-cellule-le-proposte-della-commissione-per-un-nuovo-quadro-normativo-piu-sicuro-e-rigoroso\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">29<\/span>\n<span style=\"text-align: center;\">Ago<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24958 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24958\" href=\"https:\/\/www.dejalex.com\/it\/2022\/08\/sangue-tessuti-e-cellule-le-proposte-della-commissione-per-un-nuovo-quadro-normativo-piu-sicuro-e-rigoroso\/\" target=\"_self\">SANGUE, TESSUTI E CELLULE. LE PROPOSTE DELLA COMMISSIONE PER UN NUOVO QUADRO NORMATIVO PI\u00d9 SICURO E RIGOROSO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24958 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24973_6602\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24973\" data-date=\"1659433729\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24973 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24973\" href=\"https:\/\/www.dejalex.com\/it\/2022\/08\/grail-illumina-il-tribunale-dellunione-europea-si-pronuncia-sul-primo-rinvio-ex-articolo-22-del-regolamento-sulle-concentrazioni-a-valle-delle-nuove-linee-guida\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">02<\/span>\n<span style=\"text-align: center;\">Ago<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24973 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24973\" href=\"https:\/\/www.dejalex.com\/it\/2022\/08\/grail-illumina-il-tribunale-dellunione-europea-si-pronuncia-sul-primo-rinvio-ex-articolo-22-del-regolamento-sulle-concentrazioni-a-valle-delle-nuove-linee-guida\/\" target=\"_self\">GRAIL\/ILLUMINA. IL TRIBUNALE DELL\u2019UNIONE EUROPEA SI PRONUNCIA SUL PRIMO RINVIO EX ARTICOLO 22 DEL REGOLAMENTO SULLE CONCENTRAZIONI A VALLE DELLE NUOVE LINEE GUIDA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24973 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24914_2030\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-david-maria-santoro-it filter-farmaceutico-e-life-sciences filter-nella-stampa eg-deja-row-wrapper eg-post-id-24914\" data-date=\"1659085449\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24914 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24914\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-vince-al-tribunale-di-salerno-per-glaxosmithkline\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">29<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24914 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24914\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-vince-al-tribunale-di-salerno-per-glaxosmithkline\/\" target=\"_self\">DE BERTI JACCHIA VINCE AL TRIBUNALE DI SALERNO PER GLAXOSMITHKLINE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24914 eg-deja-row-element-2\">De Berti Jacchia, con il partner David Maria Santoro, ha assistito con successo GlaxoSmithKline S.p.A. e GlaxoSmithKline Biologicals S.A. davanti al Tribunale di Salerno, in una delicata controversia in tema di responsabilit\u00e0 da prodotto farmaceutico.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24913_242\" data-skin=\"deja-row\" class=\"filterall filter-andrea-sonino-it filter-arbitrato-e-adr filter-benedetta-mazzotti-it filter-claudio-corba-colombo-it filter-diritto-del-lavoro-e-previdenza filter-farmaceutico-e-life-sciences filter-ma-it filter-michelangelo-cicogna-it filter-moda-e-lusso filter-nella-stampa filter-rachele-maggi-it eg-deja-row-wrapper eg-post-id-24913\" data-date=\"1658998421\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24913 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24913\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-con-chargeurs-nellacquisizione-di-skira-con-gitti-and-partners\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24913 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24913\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-con-chargeurs-nellacquisizione-di-skira-con-gitti-and-partners\/\" target=\"_self\">DE BERTI JACCHIA CON CHARGEURS NELL\u2019ACQUISIZIONE DI SKIRA CON GITTI AND PARTNERS<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24913 eg-deja-row-element-2\">Il team di De Berti Jacchia \u2013 che ha seguito Chargeurs Museum Solutions su tutti i profili legali dell\u2019operazione \u2013 \u00e8 stato guidato dai partner Michelangelo Cicogna\u00a0e Claudio Corba Colombo, coadiuvati dal partner Andrea Sonino per gli aspetti labour e dalle senior associate Rachele Maggi\u00a0e Benedetta Mazzotti.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24880_8381\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24880\" data-date=\"1658413360\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24880 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24880\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/la-corte-di-giustizia-mette-la-parola-fine-alla-saga-avastin-lucentis\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">21<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24880 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24880\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/la-corte-di-giustizia-mette-la-parola-fine-alla-saga-avastin-lucentis\/\" target=\"_self\">LA CORTE DI GIUSTIZIA METTE LA PAROLA FINE ALLA SAGA AVASTIN\/LUCENTIS<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24880 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-25237_5160\" data-skin=\"deja-row\" class=\"filterall filter-alisa-pestryakova-it filter-farmaceutico-e-life-sciences filter-proprieta-intellettuale filter-pubblicazioni filter-russia-it filter-russian-brief-it eg-deja-row-wrapper eg-post-id-25237\" data-date=\"1657287150\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-25237 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-25237\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/russian-government-issues-new-export-waiver-for-pharma-patent-admittedly-relying-on-article-31-bis-of-the-trips-agreement\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">08<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-25237 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-25237\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/russian-government-issues-new-export-waiver-for-pharma-patent-admittedly-relying-on-article-31-bis-of-the-trips-agreement\/\" target=\"_self\">RUSSIAN GOVERNMENT ISSUES NEW EXPORT WAIVER FOR PHARMA PATENT, ADMITTEDLY RELYING ON ARTICLE 31 BIS OF THE TRIPS AGREEMENT<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-25237 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences, Russia<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24742_2996\" data-skin=\"deja-row\" class=\"filterall filter-andrea-sonino-it filter-arbitrato-e-adr filter-benedetta-mazzotti-it filter-claudio-corba-colombo-it filter-diritto-del-lavoro-e-previdenza filter-farmaceutico-e-life-sciences filter-isabella-basilico-it filter-ma-it filter-michelangelo-cicogna-it filter-nella-stampa filter-prodotti-e-attrezzature-industriali eg-deja-row-wrapper eg-post-id-24742\" data-date=\"1657015648\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24742 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24742\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-con-ea-pharma-nellacquisizione-di-stardea\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24742 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24742\" href=\"https:\/\/www.dejalex.com\/it\/2022\/07\/de-berti-jacchia-con-ea-pharma-nellacquisizione-di-stardea\/\" target=\"_self\">DE BERTI JACCHIA CON EA PHARMA NELL\u2019ACQUISIZIONE DI STARDEA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24742 eg-deja-row-element-2\">Il team di De Berti Jacchia \u2013 che ha seguito EA Pharma su tutti i profili legali dell\u2019operazione, nella strutturazione dell\u2019operazione complessiva e il relativo coordinamento \u2013 \u00e8 stato guidato dal partner del dipartimento di ADR e Diritto del Lavoro, Michelangelo Cicogna, insieme al partner del dipartimento M&A, Claudio Corba Colombo, coadiuvati dal partner Andrea Sonino per gli aspetti labour e dalle senior associate Benedetta Mazzotti e Isabella Basilico.<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24895_5123\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24895\" data-date=\"1656081439\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24895 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24895\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-a-base-di-ferro-la-svizzera-vifor-pharma-sotto-indagine-da-parte-della-commissione\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24895 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24895\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/abuso-di-posizione-dominante-nel-mercato-dei-farmaci-a-base-di-ferro-la-svizzera-vifor-pharma-sotto-indagine-da-parte-della-commissione\/\" target=\"_self\">ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI FARMACI A BASE DI FERRO. LA SVIZZERA VIFOR PHARMA SOTTO INDAGINE DA PARTE DELLA COMMISSIONE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24895 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24542_897\" data-skin=\"deja-row\" class=\"filterall filter-coronavirus-it filter-farmaceutico-e-life-sciences filter-proprieta-intellettuale filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24542\" data-date=\"1655993122\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24542 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24542\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/proprieta-intellettuale-e-vaccini-contro-il-coronavirus-la-decisione-della-wto-sulla-sospensione-temporanea-dei-monopoli-brevettuali-per-i-vaccini\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24542 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24542\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/proprieta-intellettuale-e-vaccini-contro-il-coronavirus-la-decisione-della-wto-sulla-sospensione-temporanea-dei-monopoli-brevettuali-per-i-vaccini\/\" target=\"_self\">PROPRIET\u00c0 INTELLETTUALE E VACCINI CONTRO IL CORONAVIRUS. LA DECISIONE DELLA WTO SULLA SOSPENSIONE TEMPORANEA DEI MONOPOLI BREVETTUALI PER I VACCINI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24542 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24526_6825\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-24526\" data-date=\"1655299486\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24526 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24526\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/trasparenza-nelle-relazioni-tra-imprese-farmaceutiche-ed-healthcare-professionals-entra-in-vigore-il-c-d-sunshine-act\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">15<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24526 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24526\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/trasparenza-nelle-relazioni-tra-imprese-farmaceutiche-ed-healthcare-professionals-entra-in-vigore-il-c-d-sunshine-act\/\" target=\"_self\">TRASPARENZA NELLE RELAZIONI TRA IMPRESE FARMACEUTICHE ED HEALTHCARE PROFESSIONALS. ENTRA IN VIGORE IL C.D. \u201cSUNSHINE ACT\u201d<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24526 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24887_8828\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24887\" data-date=\"1654353031\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24887 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24887\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/il-regolamento-123-2022-e-il-rafforzamento-del-mandato-dellema\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">04<\/span>\n<span style=\"text-align: center;\">Giu<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24887 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24887\" href=\"https:\/\/www.dejalex.com\/it\/2022\/06\/il-regolamento-123-2022-e-il-rafforzamento-del-mandato-dellema\/\" target=\"_self\">IL REGOLAMENTO 123\/2022 E IL RAFFORZAMENTO DEL MANDATO DELL\u2019EMA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24887 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24246_3849\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24246\" data-date=\"1652716298\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24246 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24246\" href=\"https:\/\/www.dejalex.com\/it\/2022\/05\/la-corte-di-giustizia-si-pronuncia-sul-potere-delle-autorita-giudiziarie-nazionali-di-emettere-provvedimenti-di-urgenza-per-prevenire-violazioni-imminenti-dei-diritti-di-proprieta-intellettuale\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">16<\/span>\n<span style=\"text-align: center;\">Mag<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24246 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24246\" href=\"https:\/\/www.dejalex.com\/it\/2022\/05\/la-corte-di-giustizia-si-pronuncia-sul-potere-delle-autorita-giudiziarie-nazionali-di-emettere-provvedimenti-di-urgenza-per-prevenire-violazioni-imminenti-dei-diritti-di-proprieta-intellettuale\/\" target=\"_self\">LA CORTE DI GIUSTIZIA SI PRONUNCIA SUL POTERE DELLE AUTORIT\u00c0 GIUDIZIARIE NAZIONALI DI EMETTERE PROVVEDIMENTI DI URGENZA PER PREVENIRE VIOLAZIONI IMMINENTI DEI DIRITTI DI PROPRIET\u00c0 INTELLETTUALE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24246 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24394_3310\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-compliance-it filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24394\" data-date=\"1652459455\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24394 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24394\" href=\"https:\/\/www.dejalex.com\/it\/2022\/05\/le-principali-novita-2022-del-codice-deontologico-di-farmindustria\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Mag<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24394 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24394\" href=\"https:\/\/www.dejalex.com\/it\/2022\/05\/le-principali-novita-2022-del-codice-deontologico-di-farmindustria\/\" target=\"_self\">LE PRINCIPALI NOVIT\u00c0 2022 DEL CODICE DEONTOLOGICO DI FARMINDUSTRIA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24394 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Compliance, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-24373_4416\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-24373\" data-date=\"1651158953\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-24373 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-24373\" href=\"https:\/\/www.dejalex.com\/it\/2022\/04\/licenze-obbligatorie-la-commissione-avvia-una-nuova-consultazione-pubblica\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Apr<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-24373 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-24373\" href=\"https:\/\/www.dejalex.com\/it\/2022\/04\/licenze-obbligatorie-la-commissione-avvia-una-nuova-consultazione-pubblica\/\" target=\"_self\">LICENZE OBBLIGATORIE. LA COMMISSIONE AVVIA UNA NUOVA CONSULTAZIONE PUBBLICA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-24373 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23987_3592\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23987\" data-date=\"1648562457\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23987 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23987\" href=\"https:\/\/www.dejalex.com\/it\/2022\/03\/certificati-protettivi-complementari-la-commissione-avvia-una-nuova-consultazione-pubblica\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">29<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23987 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23987\" href=\"https:\/\/www.dejalex.com\/it\/2022\/03\/certificati-protettivi-complementari-la-commissione-avvia-una-nuova-consultazione-pubblica\/\" target=\"_self\">CERTIFICATI PROTETTIVI COMPLEMENTARI. LA COMMISSIONE AVVIA UNA NUOVA CONSULTAZIONE PUBBLICA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23987 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23899_5806\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23899\" data-date=\"1647427208\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23899 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23899\" href=\"https:\/\/www.dejalex.com\/it\/2022\/03\/medicinali-per-uso-umano-lag-szpunar-si-pronuncia-sulla-pubblicita-che-incoraggia-lacquisto-di-medicinali-facendo-leva-sul-loro-prezzo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">16<\/span>\n<span style=\"text-align: center;\">Mar<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23899 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23899\" href=\"https:\/\/www.dejalex.com\/it\/2022\/03\/medicinali-per-uso-umano-lag-szpunar-si-pronuncia-sulla-pubblicita-che-incoraggia-lacquisto-di-medicinali-facendo-leva-sul-loro-prezzo\/\" target=\"_self\">MEDICINALI PER USO UMANO. L\u2019AG SZPUNAR SI PRONUNCIA SULLA PUBBLICIT\u00c0 CHE INCORAGGIA L\u2019ACQUISTO DI MEDICINALI FACENDO LEVA SUL LORO PREZZO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23899 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23635_2658\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23635\" data-date=\"1645609639\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23635 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23635\" href=\"https:\/\/www.dejalex.com\/it\/2022\/02\/lacquisizione-grail-illumina-e-le-misure-provvisorie-della-commissione-confermano-la-policy-di-contrasto-alle-pratiche-di-gun-jumping\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">23<\/span>\n<span style=\"text-align: center;\">Feb<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23635 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23635\" href=\"https:\/\/www.dejalex.com\/it\/2022\/02\/lacquisizione-grail-illumina-e-le-misure-provvisorie-della-commissione-confermano-la-policy-di-contrasto-alle-pratiche-di-gun-jumping\/\" target=\"_self\">L\u2019ACQUISIZIONE GRAIL\/ILLUMINA E LE MISURE PROVVISORIE DELLA COMMISSIONE CONFERMANO LA POLICY DI CONTRASTO ALLE PRATICHE DI GUN JUMPING<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23635 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23559_928\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23559\" data-date=\"1644591383\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23559 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23559\" href=\"https:\/\/www.dejalex.com\/it\/2022\/02\/importazione-parallela-di-medicinali-lag-szpunar-si-pronuncia-sul-riconfezionamento-del-prodotto-contrassegnato-dal-marchio-e-sui-diritti-del-titolare-di-questo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">11<\/span>\n<span style=\"text-align: center;\">Feb<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23559 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23559\" href=\"https:\/\/www.dejalex.com\/it\/2022\/02\/importazione-parallela-di-medicinali-lag-szpunar-si-pronuncia-sul-riconfezionamento-del-prodotto-contrassegnato-dal-marchio-e-sui-diritti-del-titolare-di-questo\/\" target=\"_self\">IMPORTAZIONE PARALLELA DI MEDICINALI. L\u2019AG SZPUNAR SI PRONUNCIA SUL RICONFEZIONAMENTO DEL PRODOTTO CONTRASSEGNATO DAL MARCHIO E SUI DIRITTI DEL TITOLARE DI QUESTO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23559 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23318_8968\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23318\" data-date=\"1643020111\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23318 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23318\" href=\"https:\/\/www.dejalex.com\/it\/2022\/01\/uso-improprio-di-brevetti-e-antitrust-negli-usa-caso-pharmavite-c-bausch-lomb-incorporated-e-consumer-healthcare\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23318 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23318\" href=\"https:\/\/www.dejalex.com\/it\/2022\/01\/uso-improprio-di-brevetti-e-antitrust-negli-usa-caso-pharmavite-c-bausch-lomb-incorporated-e-consumer-healthcare\/\" target=\"_self\">USO IMPROPRIO DI BREVETTI E ANTITRUST NEGLI USA (CASO PHARMAVITE C. BAUSCH & LOMB INCORPORATED E CONSUMER HEALTHCARE)<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23318 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Contenzioso, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23253_65\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23253\" data-date=\"1642073689\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23253 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23253\" href=\"https:\/\/www.dejalex.com\/it\/2022\/01\/sperimentazioni-cliniche-oramai-alle-porte-lentrata-in-vigore-del-nuovo-regolamento-536-2014\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">13<\/span>\n<span style=\"text-align: center;\">Gen<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23253 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23253\" href=\"https:\/\/www.dejalex.com\/it\/2022\/01\/sperimentazioni-cliniche-oramai-alle-porte-lentrata-in-vigore-del-nuovo-regolamento-536-2014\/\" target=\"_self\">SPERIMENTAZIONI CLINICHE. ORAMAI ALLE PORTE L\u2019ENTRATA IN VIGORE DEL NUOVO REGOLAMENTO 536\/2014<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23253 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-23081_2141\" data-skin=\"deja-row\" class=\"filterall filter-contenzioso filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-23081\" data-date=\"1639590099\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-23081 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-23081\" href=\"https:\/\/www.dejalex.com\/it\/2021\/12\/farmacovigilanza-la-corte-di-giustizia-si-pronuncia-sulla-proporzionalita-di-misure-di-effetto-equivalente-ad-una-restrizione-quantitativa-in-caso-di-cessazione-automatica-dellaic\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">15<\/span>\n<span style=\"text-align: center;\">Dic<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-23081 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-23081\" href=\"https:\/\/www.dejalex.com\/it\/2021\/12\/farmacovigilanza-la-corte-di-giustizia-si-pronuncia-sulla-proporzionalita-di-misure-di-effetto-equivalente-ad-una-restrizione-quantitativa-in-caso-di-cessazione-automatica-dellaic\/\" target=\"_self\">FARMACOVIGILANZA. LA CORTE DI GIUSTIZIA SI PRONUNCIA SULLA PROPORZIONALIT\u00c0 DI MISURE DI EFFETTO EQUIVALENTE AD UNA RESTRIZIONE QUANTITATIVA IN CASO DI CESSAZIONE AUTOMATICA DELL\u2019AIC PER L\u2019IMPORTAZIONE PARALLELA DI MEDICINALI PER USO UMANO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-23081 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Contenzioso<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-22613_477\" data-skin=\"deja-row\" class=\"filterall filter-coronavirus-it filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it filter-ue-e-politiche-generali eg-deja-row-wrapper eg-post-id-22613\" data-date=\"1637573365\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-22613 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-22613\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/gli-aiuti-di-stato-nella-lotta-al-coronavirus-e-la-sesta-modifica-del-temporary-framework\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">22<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-22613 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-22613\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/gli-aiuti-di-stato-nella-lotta-al-coronavirus-e-la-sesta-modifica-del-temporary-framework\/\" target=\"_self\">GLI AIUTI DI STATO NELLA LOTTA AL CORONAVIRUS E LA SESTA MODIFICA DEL TEMPORARY FRAMEWORK<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-22613 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Coronavirus, UE e Politiche Generali, Farmaceutico e Life Sciences<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-22474_9143\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-22474\" data-date=\"1637146493\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-22474 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-22474\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-ed-il-rafforzamento-del-servizio-sanitario-nazionale\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">17<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-22474 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-22474\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-ed-il-rafforzamento-del-servizio-sanitario-nazionale\/\" target=\"_self\">LA LEGGE ANNUALE PER IL MERCATO E LA CONCORRENZA 2021 ED IL RAFFORZAMENTO DEL SERVIZIO SANITARIO NAZIONALE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-22474 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-22447_7560\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-agro-alimentare filter-proprieta-intellettuale filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-22447\" data-date=\"1636971102\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-22447 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-22447\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/altezza-inventiva-dati-post-pubblicati-e-plausibilita-in-un-recente-rinvio-allenlarged-board-of-appeal-dellepo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">15<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-22447 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-22447\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/altezza-inventiva-dati-post-pubblicati-e-plausibilita-in-un-recente-rinvio-allenlarged-board-of-appeal-dellepo\/\" target=\"_self\">ALTEZZA INVENTIVA, DATI POST-PUBBLICATI E PLAUSIBILIT\u00c0 IN UN RECENTE RINVIO ALL\u2019ENLARGED BOARD OF APPEAL DELL\u2019EPO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-22447 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences, Agro-alimentare<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-22462_643\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-22462\" data-date=\"1636713104\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-22462 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-22462\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-il-settore-farmaceutico\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">12<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-22462 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-22462\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-il-settore-farmaceutico\/\" target=\"_self\">LA LEGGE ANNUALE PER IL MERCATO E LA CONCORRENZA 2021 E IL SETTORE FARMACEUTICO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-22462 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-22396_8463\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-compliance-it filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it eg-deja-row-wrapper eg-post-id-22396\" data-date=\"1636367077\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-22396 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-22396\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/malattie-rare-il-nuovo-testo-unico-e-legge\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">08<\/span>\n<span style=\"text-align: center;\">Nov<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-22396 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-22396\" href=\"https:\/\/www.dejalex.com\/it\/2021\/11\/malattie-rare-il-nuovo-testo-unico-e-legge\/\" target=\"_self\">MALATTIE RARE. IL NUOVO TESTO UNICO \u00c8 LEGGE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-22396 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Compliance, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21956_7382\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21956\" data-date=\"1632474429\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21956 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21956\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-le-proposte-dellagcm-per-il-rafforzamento-del-servizio-sanitario-nazionale\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">24<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21956 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21956\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-le-proposte-dellagcm-per-il-rafforzamento-del-servizio-sanitario-nazionale\/\" target=\"_self\">LA LEGGE ANNUALE PER IL MERCATO E LA CONCORRENZA 2021 E LE PROPOSTE DELL\u2019AGCM PER IL RAFFORZAMENTO DEL SERVIZIO SANITARIO NAZIONALE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21956 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21936_6989\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-proprieta-intellettuale filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21936\" data-date=\"1632213316\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21936 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21936\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/accordi-pay-for-delay-il-competition-appeal-tribunal-britannico-conferma-la-decisione-della-competition-and-markets-authority-in-tema-di-abuso-di-posizione-dominante-nel-mercato-dei-medicinali-generi\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">21<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21936 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21936\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/accordi-pay-for-delay-il-competition-appeal-tribunal-britannico-conferma-la-decisione-della-competition-and-markets-authority-in-tema-di-abuso-di-posizione-dominante-nel-mercato-dei-medicinali-generi\/\" target=\"_self\">ACCORDI PAY-FOR-DELAY. IL COMPETITION APPEAL TRIBUNAL BRITANNICO CONFERMA LA DECISIONE DELLA COMPETITION AND MARKETS AUTHORITY IN TEMA DI ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI MEDICINALI GENERICI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21936 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Propriet\u00e0 Intellettuale, Societ\u00e0<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21945_7489\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21945\" data-date=\"1632127298\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21945 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21945\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/le-proposte-dellagcm-per-la-riforma-della-concorrenza-nel-settore-farmaceutico-e-il-disegno-di-legge-per-il-mercato-2021\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">20<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21945 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21945\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/le-proposte-dellagcm-per-la-riforma-della-concorrenza-nel-settore-farmaceutico-e-il-disegno-di-legge-per-il-mercato-2021\/\" target=\"_self\">LE PROPOSTE DELL\u2019AGCM PER LA RIFORMA DELLA CONCORRENZA NEL SETTORE FARMACEUTICO E IL DISEGNO DI LEGGE PER IL MERCATO 2021<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21945 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Farmaceutico e Life Sciences, Societ\u00e0, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21920_3323\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-gare-e-appalti-pubblici filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21920\" data-date=\"1631629836\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21920 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21920\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-le-segnalazioni-e-proposte-dellagcm\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">14<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21920 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21920\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/la-legge-annuale-per-il-mercato-e-la-concorrenza-2021-e-le-segnalazioni-e-proposte-dellagcm\/\" target=\"_self\">LA LEGGE ANNUALE PER IL MERCATO E LA CONCORRENZA 2021 E LE SEGNALAZIONI E PROPOSTE DELL\u2019AGCM<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21920 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Gare e Appalti Pubblici, Societ\u00e0<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21878_6910\" data-skin=\"deja-row\" class=\"filterall filter-coronavirus-it filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-responsabilita-da-prodotto-sicurezza filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21878\" data-date=\"1630655994\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21878 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21878\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/scudo-penale-e-obbligo-vaccinale-per-il-personale-medico-e-sanitario-le-disposizioni-italiane-e-il-contesto-europeo\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">03<\/span>\n<span style=\"text-align: center;\">Set<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21878 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21878\" href=\"https:\/\/www.dejalex.com\/it\/2021\/09\/scudo-penale-e-obbligo-vaccinale-per-il-personale-medico-e-sanitario-le-disposizioni-italiane-e-il-contesto-europeo\/\" target=\"_self\">SCUDO PENALE E OBBLIGO VACCINALE PER IL PERSONALE MEDICO E SANITARIO. LE DISPOSIZIONI ITALIANE E IL CONTESTO EUROPEO<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21878 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Coronavirus, Farmaceutico e Life Sciences, Responsabilit\u00e0 da prodotto e sicurezza, Societ\u00e0<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21773_241\" data-skin=\"deja-row\" class=\"filterall filter-consumatori-e-vendita-al-dettaglio filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-pubblicazioni filter-roberto-jacchia-it filter-trasporti-assicurazioni-e-logistica eg-deja-row-wrapper eg-post-id-21773\" data-date=\"1628156338\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21773 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21773\" href=\"https:\/\/www.dejalex.com\/it\/2021\/08\/assicurazioni-sanitarie-lagcm-sanziona-intesa-sanpaolo-rbm-salute-e-previmedical-per-pratiche-commerciali-scorrette\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">05<\/span>\n<span style=\"text-align: center;\">Ago<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21773 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21773\" href=\"https:\/\/www.dejalex.com\/it\/2021\/08\/assicurazioni-sanitarie-lagcm-sanziona-intesa-sanpaolo-rbm-salute-e-previmedical-per-pratiche-commerciali-scorrette\/\" target=\"_self\">ASSICURAZIONI SANITARIE. L'AGCM SANZIONA INTESA SANPAOLO RBM SALUTE E PREVIMEDICAL PER PRATICHE COMMERCIALI SCORRETTE<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21773 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> EU and Competition, Pharmaceuticals and Life Sciences, Consumer and Retail, Transport, Insurance and Logistics<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21734_2723\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21734\" data-date=\"1627889165\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21734 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21734\" href=\"https:\/\/www.dejalex.com\/it\/2021\/08\/lautorita-per-i-consumatori-e-i-mercati-olandese-sanziona-la-leadiant-per-un-abuso-di-posizione-dominante-nel-mercato-dei-medicinali-orfani\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">02<\/span>\n<span style=\"text-align: center;\">Ago<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21734 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21734\" href=\"https:\/\/www.dejalex.com\/it\/2021\/08\/lautorita-per-i-consumatori-e-i-mercati-olandese-sanziona-la-leadiant-per-un-abuso-di-posizione-dominante-nel-mercato-dei-medicinali-orfani\/\" target=\"_self\">L\u2019AUTORIT\u00c0 PER I CONSUMATORI E I MERCATI OLANDESE SANZIONA LA LEADIANT PER UN ABUSO DI POSIZIONE DOMINANTE NEL MERCATO DEI MEDICINALI ORFANI<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21734 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Pharmaceuticals and Life Sciences, Society, Perspectives<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21719_9402\" data-skin=\"deja-row\" class=\"filterall filter-antonella-terranova-it filter-arbitrato-e-adr filter-contenzioso filter-david-maria-santoro-it filter-diritto-del-lavoro-e-previdenza filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-gaspare-roma-it filter-guido-callegari-it filter-it-tmt-it filter-maria-cristina-franchini-it filter-michelangelo-cicogna-it filter-nella-stampa filter-premi filter-proprieta-intellettuale filter-roberto-jacchia-it filter-societario-e-commerciale eg-deja-row-wrapper eg-post-id-21719\" data-date=\"1627654994\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21719 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21719\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/leaders-league-ranked-firm-2021\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">30<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21719 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21719\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/leaders-league-ranked-firm-2021\/\" target=\"_self\">LEADERS LEAGUE: RANKED FIRM 2021<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21719 eg-deja-row-element-2\"><br \/><\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21710_2068\" data-skin=\"deja-row\" class=\"filterall filter-diritto-europeo-e-della-concorrenza filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-sostenibilita eg-deja-row-wrapper eg-post-id-21710\" data-date=\"1627650997\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21710 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21710\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/primo-rinvio-ex-articolo-22-del-regolamento-europeo-sulle-concentrazioni-la-commissione-apre-unindagine-sullacquisizione-grail-illumina\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">30<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21710 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21710\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/primo-rinvio-ex-articolo-22-del-regolamento-europeo-sulle-concentrazioni-la-commissione-apre-unindagine-sullacquisizione-grail-illumina\/\" target=\"_self\">PRIMO RINVIO EX ARTICOLO 22 DEL REGOLAMENTO EUROPEO SULLE CONCENTRAZIONI. LA COMMISSIONE APRE UN\u2019INDAGINE SULL\u2019ACQUISIZIONE GRAIL\/ILLUMINA<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21710 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<li id=\"eg-1-post-id-21655_6122\" data-skin=\"deja-row\" class=\"filterall filter-farmaceutico-e-life-sciences filter-prospettive filter-pubblicazioni filter-roberto-jacchia-it filter-societa eg-deja-row-wrapper eg-post-id-21655\" data-date=\"1627489569\">\n<div class=\"esg-entry-content eg-deja-row-content\">\n\t\t\t\t<h6 class=\"esg-absolute eg-post-21655 eg-deja-row-element-1-a\"><a class=\"eg-deja-row-element-1 eg-post-21655\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/licenze-obbligatorie-per-i-brevetti-ed-emergenze-sanitarie-via-libera-col-nuovo-emendamento-al-decreto-recovery\/\" target=\"_self\"><span style=\"font-weight: 800; display: block; text-align: center;\">28<\/span>\n<span style=\"text-align: center;\">Lug<\/span><\/a><\/h6>\n\t\t\t\t<h5 class=\"esg-content eg-post-21655 eg-deja-row-element-4-a\"><a class=\"eg-deja-row-element-4 eg-post-21655\" href=\"https:\/\/www.dejalex.com\/it\/2021\/07\/licenze-obbligatorie-per-i-brevetti-ed-emergenze-sanitarie-via-libera-col-nuovo-emendamento-al-decreto-recovery\/\" target=\"_self\">LICENZE OBBLIGATORIE PER I BREVETTI ED EMERGENZE SANITARIE. VIA LIBERA COL NUOVO EMENDAMENTO AL DECRETO RECOVERY<\/a><\/h5>\n\t\t\t\t<div class=\"esg-content eg-post-21655 eg-deja-row-element-2\"><i  class=\"x-icon x-icon-tag\" data-x-icon-s=\"&#xf02b;\" aria-hidden=\"true\"><\/i> Pharmaceuticals and Life Sciences, Society, Perspectives<\/div>\n<\/div>    <div class=\"esg-media-cover-wrapper\">\n<div class=\"esg-entry-media\"><\/div>\n\n   <\/div>\n\n<\/li>\n<\/ul>\n<article class=\"esg-filters esg-singlefilters\" style=\"margin-top: 0px; text-align: center; \"><div class=\"esg-navigationbutton esg-left  esg-fgc-1\"  style=\"margin-left: 2.5px !important; margin-right: 2.5px !important; display: none;\"><i class=\"eg-icon-left-open\"><\/i><\/div><div class=\"esg-pagination  esg-fgc-1\" style=\"margin-left: 2.5px; margin-right: 2.5px;\"><\/div><div class=\"esg-navigationbutton esg-right  esg-fgc-1\"  style=\"margin-left: 2.5px !important; margin-right: 2.5px !important; display: none;\"><i class=\"eg-icon-right-open\"><\/i><\/div><\/article><div class=\"esg-clear-no-height\"><\/div>    <\/div>\n\n<\/article>\n<div class=\"clear\"><\/div>\n<script type=\"text\/javascript\">\nvar essapi_1_custom_post_1;\nfunction esginit_1_custom_post_1() {\njQuery(document).ready(function() {\n  var lightboxOptions = {\n        margin : [0,0,0,0],\n        buttons : [\"share\",\"thumbs\",\"close\"],\n        infobar : true,\n        loop : true,\n        slideShow : {\"autoStart\": false, \"speed\": 3000},\n        videoAutoPlay : true,\n        animationEffect : \"fade\",\n        animationDuration : 500,\n        beforeShow: function(a, c) {\n          var i = 0,\n              multiple = false;\n          a = a.slides;\n          for(var b in a) {\n            i++;\n            if (i > 1) {\n              multiple = true;\n              break;\n            }\n          }\n          if (!multiple) jQuery(\"body\").addClass(\"esgbox-single\");\n          if (c.type === \"image\") jQuery(\".esgbox-button--zoom\").show();\n          if (c.contentType === \"html\") c.$slide.addClass(\"esgbox-slide--overflow-\" + c.opts.overflow);\n        },\n        beforeLoad: function(a, b) {\n          jQuery(\"body\").removeClass(\"esg-four-by-three\");\n          if (b.opts.$orig.data(\"ratio\") === \"4:3\") jQuery(\"body\").addClass(\"esg-four-by-three\");\n        },\n        afterLoad: function() {jQuery(window).trigger(\"resize.esglb\");},\n        afterClose : function() {jQuery(\"body\").removeClass(\"esgbox-hidearrows esgbox-single\");},\n        transitionEffect : \"fade\",\n        transitionDuration : 500,\n        hash : \"group\",\n        arrows : true,\n        wheel : false,\n        baseClass : \"esgbox-container-1-custom_post\",\n        captionPosition : \"bottom\",\n        overflow : \"auto\",\n  };\n\n  jQuery(\"#esg-grid-1-custom_post-1\").data(\"lightboxsettings\", lightboxOptions);\n\n  essapi_1_custom_post_1 = jQuery(\"#esg-grid-1-custom_post-1\").tpessential({\n        gridID:1,\n        layout:\"masonry\",\n        lazyLoad:\"off\",\n        row:5,\n        apiName: \"essapi_1_custom_post_1\",\n        loadMoreAjaxToken:\"7a96b571c0\",\n        loadMoreAjaxUrl:\"https:\/\/www.dejalex.com\/it\/wp-admin\/admin-ajax.php\",\n        loadMoreAjaxAction:\"Essential_Grid_Front_request_ajax\",\n        ajaxContentTarget:\"ess-grid-ajax-container-\",\n        ajaxScrollToOffset:\"0\",\n        ajaxCloseButton:\"off\",\n        ajaxContentSliding:\"on\",\n        ajaxScrollToOnLoad:\"on\",\n        ajaxCallbackArgument:\"off\",\n        ajaxNavButton:\"off\",\n        ajaxCloseType:\"type1\",\n        ajaxCloseInner:\"false\",\n        ajaxCloseStyle:\"light\",\n        ajaxClosePosition:\"tr\",\n        space:0,\n        pageAnimation:\"fade\",\n        videoPlaybackInGrid: \"on\",\n        videoLoopInGrid: \"on\",\n        videoPlaybackOnHover: \"off\",\n        videoInlineMute: \"on\",\n        videoInlineControls: \"off\",\n        keepLayersInline: \"off\",\n        startAnimation: \"none\",\n        startAnimationSpeed: 1000,\n        startAnimationDelay: 100,\n        startAnimationType: \"item\",\n        animationType: \"item\",\n        paginationScrollToTop:\"off\",\n        paginationAutoplay:\"off\",\n        spinner:\"spinner0\",\n        minVisibleItems:3,\n        lightBoxMode:\"single\",\n        lightboxHash:\"group\",\n        lightboxPostMinWid:\"75%\",\n        lightboxPostMaxWid:\"75%\",\n        lightboxSpinner:\"off\",\n        lightBoxFeaturedImg:\"off\",\n        lightBoxPostTitle:\"off\",\n        lightBoxPostTitleTag:\"h2\",\n        lightboxMargin : \"0|0|0|0\",\n        lbContentPadding : \"0|0|0|0\",\n        lbContentOverflow : \"auto\",\n        animSpeed:1000,\n        delayBasic:1,\n        mainhoverdelay:1,\n        filterType:\"single\",\n        showDropFilter:\"hover\",\n        filterGroupClass:\"esg-fgc-1\",\n        filterNoMatch:\"No Items for the Selected Filter\",\n        filterDeepLink:\"off\",\n        hideMarkups: \"on\",\n        inViewport: true,\n        viewportBuffer: 20,\n        youtubeNoCookie:\"false\",\n        convertFilterMobile:false,\n        convertFilterMobileWidth:768,\n        paginationSwipe: \"off\",\n        paginationDragVer: \"on\",\n        pageSwipeThrottle: 30,\n        googleFonts:['Open+Sans:300,400,600,700,800','Raleway:100,200,300,400,500,600,700,800,900','Droid+Serif:400,700'],\n        hideBlankItemsAt: \"1\",\n        responsiveEntries: [\n            { width:1900,amount:1,mmheight:0},\n            { width:1400,amount:1,mmheight:0},\n            { width:1170,amount:1,mmheight:0},\n            { width:1024,amount:1,mmheight:0},\n            { width:960,amount:1,mmheight:0},\n            { width:778,amount:1,mmheight:0},\n            { width:640,amount:1,mmheight:0},\n            { width:480,amount:1,mmheight:0},\n            ]\n  });\n\n\n});\n} \/\/ End of EsgInitScript\nvar once_1_custom_post_1 = false;\nif (document.readyState === \"loading\") document.addEventListener('readystatechange',function() { if ((document.readyState === \"interactive\" || document.readyState === \"complete\") && !once_1_custom_post_1 ) { once_1_custom_post_1 = true; esginit_1_custom_post_1();}}); else {once_1_custom_post_1 = true; esginit_1_custom_post_1();}\n<\/script>\n<\/div><div id=\"x-legacy-panel-2\" class=\"x-tab-pane hide\"  aria-hidden=\"true\" aria-labelledby=\"x-legacy-tab-2\" role=\"tabpanel\" data-x-toggleable=\"x-legacy-tab-2\">DESCRIZIONE TRACK RECORD Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.<\/p>\n<h6>Practices<\/h6>\n<p>EU&#038;Competition<\/p>\n<h6>Industries<\/h6>\n<p>Betting and Gaming<\/p>\n<hr  class=\"x-gap\" style=\"margin: 30px 0 0 0;\"><img decoding=\"async\" class=\"size-full wp-image-116 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2017\/03\/icona-logo.png\" alt=\"\" width=\"50\" srcset=\"https:\/\/www.dejalex.com\/it\/wp-content\/uploads\/2017\/03\/icona-logo.png 495w, https:\/\/www.dejalex.com\/it\/wp-content\/uploads\/2017\/03\/icona-logo-300x79.png 300w, https:\/\/www.dejalex.com\/it\/wp-content\/uploads\/2017\/03\/icona-logo-100x26.png 100w\" sizes=\"(max-width: 495px) 100vw, 495px\" \/><hr  class=\"x-gap\" style=\"margin: 30px 0 0 0;\">\n<\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":9356,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-blank-4.php","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-9814","page","type-page","status-publish","hentry","no-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/pages\/9814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=9814"}],"version-history":[{"count":10,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/pages\/9814\/revisions"}],"predecessor-version":[{"id":34592,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/pages\/9814\/revisions\/34592"}],"up":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/pages\/9356"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=9814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}